var title_f14_27_14768="Phytophotodermatitis";
var content_f14_27_14768=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76127&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76127&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Phytophotodermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 292px; height: 339px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This burn-like skin lesion occurs when sunlight interacts with photosensitizing compounds found in certain fruits or vegetables (eg, limes, lemons, figs, parsnips, celery). The pattern of lesion corresponds to the contact (eg, streaks from dripping juice, handprints from adults handling the sensitizing material and then the child), or around the hands and mouth after the child handles or ingests the agent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Erin E Endom, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_27_14768=[""].join("\n");
var outline_f14_27_14768=null;
var title_f14_27_14769="Urinary anatomy pedi PI";
var content_f14_27_14769=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F65630&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F65630&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Anatomy of the urinary tract in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 402px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These drawings show the parts of the urinary tract in a girl and a boy. Urine is made by the kidneys. It passes from the kidneys into the bladder through two tubes called the ureters. Then it leaves the bladder through another tube, called the urethra.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_27_14769=[""].join("\n");
var outline_f14_27_14769=null;
var title_f14_27_14770="Pediatric algorithm for septic shock";
var content_f14_27_14770=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F65304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F65304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 586px\">",
"   <div class=\"ttl\">",
"    Pediatric Advance Lifes Support septic shock algorithm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 566px; height: 613px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     *",
"     <strong>",
"      NOTE",
"     </strong>",
"     : Fluid refractory and dopamine- or norepinephrine-dependent shock defines patient at risk for adrenal insufficiency. Draw baseline cortisol; consider ACTH stimulation test if unsure of need for steroids. If adrenal insufficiency is suspected give hydrocortisone &cong;2 mg/kg bolus IV; maximum 100 mg.",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: American Academy of Pediatrics, American Heart Association. Management of Shock. In: Pediatric Advanced Life Support Provider Manual, Chameides L, Samson RA, Schexnayder S, Hazinski MF (Eds), American Heart Association, 2011. Copyright &copy; 2011 American Heart Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_27_14770=[""].join("\n");
var outline_f14_27_14770=null;
var title_f14_27_14771="Dry eye conjunctival vessels";
var content_f14_27_14771=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Dry eye disease with prominent conjunctival vessels indicating irritation of ocular surface",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 231px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_27_14771=[""].join("\n");
var outline_f14_27_14771=null;
var title_f14_27_14772="Pentastarch: Drug information";
var content_f14_27_14772=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pentastarch: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?22/48/23299?source=see_link\">",
"    see \"Pentastarch: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F207901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pentaspan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F207907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Plasma Volume Expander, Colloid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F207903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Plasma volume expansion: I.V.: Usual: 500-2000 mL administered at a rate up to 20 mL/kg/hour (maximum daily dose: 28 mL/kg or 2000 mL)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F207904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F12806081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Specific dosing recommendations not provided in manufacturer labeling; contraindicated in patients with oliguria or anuria not related to hypovolemia.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F12806127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in NS:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pentaspan&reg;: 10% (250 mL, 500 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F207889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F12806126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F12806082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer I.V. at a rate up to 20 mL/kg/hour (eg, in acute hemorrhagic shock). Replace administration apparatus at least once every 24 hours.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F207896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunctive treatment in the management of shock",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F12805820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Angina, edema, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Anxiety, chills, dizziness, fatigue, fever, headache, insomnia, malaise, shakiness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Endocrine &amp; metabolic: Amylase increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Diarrhea, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hematologic: Coagulation disorder, hemorrhage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hepatic: Bilirubin increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Anaphylactic/anaphylactoid reaction, hypersensitivity (hypotension, urticaria, wheezing)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F12805661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to hydroxyethyl starch or any component of the formulation; bleeding disorders; congestive heart failure where volume overload is a concern; oliguria or anuria not related to hypovolemia",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F12805724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fluid overload: Administration can cause fluid overload; use with caution in patients at risk from overexpansion of blood volume (eg, very young patients, aged patients, or those with heart failure).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic: Large volumes of pentastarch may cause reduction in hemoglobin concentration, coagulation factors, and other plasma proteins due to hemodilution; coagulation may be impaired (eg, prolonged PT, PTT, and clotting times) and a transient prolongation of bleeding time may be observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity: Anaphylactic/anaphylactoid reactions have been reported; discontinue use immediately with signs of hypersensitivity and administer appropriate therapy. Patients allergic to corn may be allergic to pentastarch.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding disorders (eg, von Willebrand&rsquo;s disease): Use caution in severe bleeding disorders; may increase the risk of more bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Critically-ill patients: The use of hydroxyethyl starches (HES), including pentastarch, is associated with an increased risk of acute kidney injury (Reinhart, 2012). Additionally, in a meta-analysis of mixed critically-ill patient populations, the use of HES did not demonstrate statistically significant differences in mortality compared to crystalloid therapy (Perel, 2011). In review of clinical trials including patients with severe sepsis or septic shock, a meta-analysis of HES trials demonstrated a trend toward increased mortality (Zarychanski, 2009). In patients with severe sepsis, a trend towards higher mortality at 90 days was observed in one clinical trial comparing HES 200/0.5 (pentastarch) to Ringer&rsquo;s lactate (Brunkhorst, 2008). In addition, the use of HES 130/0.42 (Tetraspan&reg;; similar to tetrastarch) has been shown to increase mortality in patients with severe sepsis as compared to Ringer&rsquo;s acetate (Perner, 2012).  The Society of Critical Care Medicine has recommended either crystalloid or iso-oncotic colloid (natural or artificial) therapy for fluid resuscitation in patients with septic shock (Dellinger, 2008). Hyperoncotic solutions should not be used for fluid resuscitation (Reinhart, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure: Use with caution in heart failure patients; monitor closely for fluid overload.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemorrhage: Use with caution in patients with active hemorrhage; may increase the risk of more bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; may result in further reduction of coagulation factors, increasing the risk of bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; fluid status including urine output should be monitored closely. Use is contraindicated with oliguria or anuria not related to hypovolemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Not a substitute for red blood cells or coagulation factors.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F12805680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Adverse events were observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F12805681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in human breast milk is unknown; use caution.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F12806093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, heart rate, CVP, capillary refill time, cardiac index; if pulmonary artery catheter in place, monitor PCWP, SVR, and PVR; urine output, hemoglobin, hematocrit, serum electrolytes, renal function, coagulation parameters",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F207898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      HAES-steril (GB, NO);",
"     </li>",
"     <li>",
"      Haes-Steril (TW);",
"     </li>",
"     <li>",
"      Pentarch (KP);",
"     </li>",
"     <li>",
"      Pentaspan (KP);",
"     </li>",
"     <li>",
"      Voluven (AU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F12805851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Produces plasma volume expansion by virtue of its highly colloidal starch structure",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F12805853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Volume expansion: Within 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: 18-24 hours (improves hemodynamic status for 12-18 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~2 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (~70% within 24 hours; ~80% within 1 week)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Brunkhorst FM, Engel C, Bloos F, et al, \"Intensive Insulin Therapy and Pentastarch Resuscitation in Severe Sepsis,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 358(2):125-39.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/27/14772/abstract-text/18184958/pubmed\" id=\"18184958\" target=\"_blank\">",
"        18184958",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Carlet JM, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2008,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2008, 36(1):296-327; published erratum appears in",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2008, 36(4):1394-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/27/14772/abstract-text/18158437/pubmed\" id=\"18158437\" target=\"_blank\">",
"        18158437",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Rhodes A, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(2):580-637.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/27/14772/abstract-text/23353941/pubmed\" id=\"23353941\" target=\"_blank\">",
"        23353941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jungheinrich C and Neff TA, \"Pharmacokinetics of Hydroxyethyl Starch,\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2005;44(7):681-99.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/27/14772/abstract-text/15966753/pubmed\" id=\"15966753\" target=\"_blank\">",
"        15966753",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perel P and Roberts I, &ldquo;Colloids versus Crystalloids for Fluid Resuscitation in Critically Ill Patients,&rdquo;",
"      <i>",
"       Cochrane Database Syst Rev",
"      </i>",
"      , 2012, 6:CD000567.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/27/14772/abstract-text/22696320/pubmed\" id=\"22696320\" target=\"_blank\">",
"        22696320",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perner A, Haase N, Guttormsen AB, et al, &ldquo;Hydroxyethyl Starch 130/0.4 versus Ringer&rsquo;s Acetate in Severe Sepsis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 367(2):124-34; published erratum appears in",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 367(5):481.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/27/14772/abstract-text/22738085/pubmed\" id=\"22738085\" target=\"_blank\">",
"        22738085",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reinhart K, Perner A, Sprung CL, et al, &ldquo;Consensus Statement of the ESICM Task Force on Colloid Volume Therapy in Critically Ill Patients,&rdquo;",
"      <i>",
"       Intensive Care Med",
"      </i>",
"      , 2012, 38(3):368-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/27/14772/abstract-text/22323076/pubmed\" id=\"22323076\" target=\"_blank\">",
"        22323076",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Strauss RG, Pennell BJ, and Stump DC, \"A Randomized, Blinded Trial Comparing the Hemostatic Effects of Pentastarch Versus Hetastarch,\"",
"      <i>",
"       Transfusion",
"      </i>",
"      , 2002, 42(1):27-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/27/14772/abstract-text/11896309/pubmed\" id=\"11896309\" target=\"_blank\">",
"        11896309",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zarychanski R, Turgeon AF, Fergusson DA, et al, &ldquo;Renal Outcomes and Mortality Following Hydroxyethyl Starch Resuscitation of Critically Ill Patients: Systematic Review and Meta-Analysis of Randomized Trials&rdquo;",
"      <b>",
"       ATTENTION:",
"      </b>",
"      The analysis and conclusions of this article are being revised by the authors. This is due to the journal Anesthesia and Analgesia's retraction of a paper by Dr. Joachim Boldt, an author in seven of the studies analyzed in this review. As such, the editors of Open Medicine recommend interpreting this review with extreme caution until Zarychanski et al. publish a new analysis and interpretation in Open Medicine. For more information, see Anesthesia and Analgesia's press release.",
"      <i>",
"       Open Med",
"      </i>",
"      , 2009, 3(4):e196-209.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/27/14772/abstract-text/21688756/pubmed\" id=\"21688756\" target=\"_blank\">",
"        21688756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10203 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-221.179.173.170-9A4DD99832-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_27_14772=[""].join("\n");
var outline_f14_27_14772=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207901\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207907\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207903\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207904\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12806081\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12806127\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207889\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12806126\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12806082\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207896\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12805820\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12805661\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12805724\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299845\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222215\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12805680\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12805681\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12806093\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207898\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12805851\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12805853\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10203\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10203|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/48/23299?source=related_link\">",
"      Pentastarch: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_27_14773="Uremic polyneuropathy";
var content_f14_27_14773=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Uremic polyneuropathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/27/14773/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/27/14773/contributors\">",
"     Biff F Palmer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/27/14773/contributors\">",
"     William L Henrich, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/27/14773/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/27/14773/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/27/14773/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/27/14773/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/27/14773/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysfunction of the peripheral nervous system induced by uremia commonly occurs in patients with end-stage renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14773/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Peripheral polyneuropathy generally develops only in advanced renal failure and is an indication to initiate dialysis. However, patients already being adequately dialyzed are also at some risk, although the neural dysfunction is often subclinical and detectable only by electrophysiologic studies.",
"   </p>",
"   <p>",
"    Rarely, patients undergoing maintenance dialysis develop a rapidly evolving polyneuropathy simulating the Guillain-Barre syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14773/abstract/4\">",
"     4",
"    </a>",
"    ]. This problem is reminiscent of past experience when underdialysis was common, a setting in which a devastating neuropathy could develop with possible progression to life-threatening quadriplegia. Thus, the onset of even mild neuropathy, if otherwise unexplained, requires a review of the dialysis prescription to ensure that the patient is being adequately dialyzed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=see_link\">",
"     \"Kt/V and the adequacy of hemodialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/7/1144?source=see_link\">",
"     \"Prescribed versus delivered dialysis: Importance of dialysis time\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uremic peripheral neuropathy is a distal, symmetrical, mixed sensorimotor neuropathy. It occurs more commonly in men and is independent of the underlying disease. As with other neuropathies, injury is directly related to axon length; thus, longer axons are affected first, resulting in symptoms that are more prominent in the lower extremities. The sensory symptoms &mdash; paresthesias, burning sensations, and pain &mdash; tend to precede the motor symptoms. The initial finding in uremic polyneuropathy is loss of position and vibration sense in the toes and decreased deep tendon reflexes, beginning with the Achilles reflex. Once the sensory defects have moved to or above the knees, the hands may become involved. This sequence of progression is a reflection of axon length.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Sensory syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sensory dysfunction in uremic polyneuropathy may present as one of several distinct syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14773/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The restless leg syndrome refers to a persistent and extremely uncomfortable sensation in the lower extremities that can only be relieved by movement of the legs. The symptoms tend to be more prominent at night and may interfere with sleep [",
"      <a class=\"abstract\" href=\"UTD.htm?14/27/14773/abstract/5\">",
"       5",
"      </a>",
"      ]. This syndrome is extremely common among dialysis patients, with a reported incidence ranging from 6 to 60 percent, although the prevalence may be decreasing [",
"      <a class=\"abstract\" href=\"UTD.htm?14/27/14773/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]. Affected patients may have decreased survival and quality of life [",
"      <a class=\"abstract\" href=\"UTD.htm?14/27/14773/abstract/8\">",
"       8",
"      </a>",
"      ]. Reported associations include increased dialysis duration and body weight, iron deficiency, and smoking history [",
"      <a class=\"abstract\" href=\"UTD.htm?14/27/14773/abstract/9,10\">",
"       9,10",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32554?source=see_link\">",
"       \"Restless legs syndrome\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The burning foot syndrome refers to severe pain and a burning sensation in the distal lower extremities. The common occurrence of this syndrome in the early days of dialysis was probably due to acquired thiamine deficiency, since this vitamin is water soluble and is well dialyzed. The routine administration of thiamine and other water soluble vitamins to patients with end-stage renal disease has essentially eliminated this disorder. In addition to its peripheral effects, thiamine deficiency can also lead to the development of acute Wernicke's encephalopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?14/27/14773/abstract/11,12\">",
"       11,12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Paradoxical heat sensation is another sensory manifestation of uremic neuropathy. Application of low temperature stimuli evokes the sensation of high temperature in this condition [",
"      <a class=\"abstract\" href=\"UTD.htm?14/27/14773/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Motor symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, motor involvement usually reflects advanced disease. Loss of motor function can lead to muscle atrophy, myoclonus, and eventual paralysis. Progression to this late stage is worrisome, because complete recovery with dialysis is now unlikely. A variant has been described that is characterized by an accelerated predominately motor polyneuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14773/abstract/11\">",
"     11",
"    </a>",
"    ]. This disorder has been primarily described in patients who are critically ill, often septic, and suffering from multiple organ failure. The degree of renal failure may only be mild so that factors other than uremia also must be important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uremic polyneuropathy is difficult to distinguish from other diseases that can lead to renal failure and simultaneously affect peripheral nerve function, such as diabetes mellitus, systemic lupus erythematosus, multiple myeloma, and amyloidosis. In these instances, injury to the peripheral nerves may be additive [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14773/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Electrophysiologic studies are the most sensitive way to detect uremic neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14773/abstract/15\">",
"     15",
"    </a>",
"    ]. Almost 80 percent of patients have electrophysiologic signs of impaired nerve function, although only one-half of these patients are symptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14773/abstract/16\">",
"     16",
"    </a>",
"    ]. In addition to early diagnosis, electrophysiologic testing can also be used to monitor the course of disease once renal replacement therapy is initiated.",
"   </p>",
"   <p>",
"    Motor nerve conduction velocity, often measured in the peroneal nerve, is the most common parameter used to assess motor function. Slowing of nerve conduction velocity usually parallels the decline in creatinine clearance; more than 50 percent of patients are abnormal when the creatinine clearance falls to 10",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14773/abstract/17\">",
"     17",
"    </a>",
"    ]. Sensory nerve conduction velocity of the sural nerve is even more sensitive in detecting early dysfunction, but is not as widely used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathologic features of uremic polyneuropathy consist of demyelination and axonal degeneration. Although the issue is not totally resolved, it has been suggested axonal degeneration is the primary abnormality leading to secondary segmental demyelination. These changes are most severe distally, possibly reflecting dysfunction at the level of the nerve cell body with a resultant dying-back phenomenon. In addition to peripheral nerve involvement, demyelination of the posterior columns and other portions of the central nervous system has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14773/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The metabolic and chemical basis underlying the development of uremic neuropathy has remained elusive [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14773/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition to thiamine deficiency described above, other factors that may contribute to the development of uremic neuropathy include decreased transketolase activity, reduced plasma concentrations of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/25/9618?source=see_link\">",
"     biotin",
"    </a>",
"    and zinc [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14773/abstract/18\">",
"     18",
"    </a>",
"    ], increased plasma concentrations of phenols and myoinositol, and hyperparathyroidism.",
"   </p>",
"   <p>",
"    A widely discussed hypothesis to account for the development of peripheral nerve dysfunction is the accumulation of uremic toxins of medium molecular weight. Much of the enthusiasm for this theory came from the initial observation that patients on peritoneal dialysis had a lower incidence of polyneuropathy than those on hemodialysis. The clearance of middle molecules (mol wt equal 500 to 2000 daltons) is greater with peritoneal dialysis due to the increased time of dialysis. Thus, more efficient middle molecule clearance could explain the seemingly better outcome with peritoneal dialysis.",
"   </p>",
"   <p>",
"    This hypothesis has been criticized, because of the failure to consider the contribution of residual renal function which tends to be better maintained in those on peritoneal dialysis. Even a glomerular filtration rate as low as 5",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    reflects a filtration rate of 50",
"    <span class=\"nowrap\">",
"     L/week",
"    </span>",
"    and a middle molecule clearance rate exceeding that achieved by dialysis. In addition, more recent studies directly comparing hemodialysis and peritoneal dialysis have noted a greater decline in motor nerve conduction and vibration sensation with CAPD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14773/abstract/19\">",
"     19",
"    </a>",
"    ]. Thus, the pathogenetic importance of middle molecule retention remains unresolved [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14773/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Institution of hemodialysis will either stabilize or improve symptoms in patients with uremic polyneuropathy. The extent of recovery is directly related to the degree and extent of dysfunction prior to the initiation of dialysis. Complete resolution may occur when there are only mild sensory symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14773/abstract/1\">",
"     1",
"    </a>",
"    ]. However, subclinical abnormalities may still be detectable by electrophysiologic testing [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14773/abstract/21\">",
"     21",
"    </a>",
"    ]. It is likely that hemodialysis and CAPD are equally effective.",
"   </p>",
"   <p>",
"    In comparison, improvement following dialysis is often incomplete even after more than 10 years in those patients with more severe neurologic symptoms. Many patients with persistent neuropathy were either not dialyzed until uremia was far advanced or were underdialyzed. The current regimen of earlier (before irreversible nerve damage has occurred) and more intensive dialysis is undoubtedly responsible for the decline in the incidence of uremic neuropathy in recent years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14773/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=see_link\">",
"     \"Kt/V and the adequacy of hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The restoration of near normal renal function with renal transplantation more consistently improves neurologic symptoms than dialysis. Even severely affected patients who are unable to ambulate may recover the ability to walk. The clinical course after transplantation is often biphasic. There is initial rapid improvement which occurs over days or weeks; this phase is then followed by continued, gradual improvement over a period of several months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Restless legs syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association between iron deficiency and restless legs syndrome suggests that iron therapy among dialysis patients with functional, but not absolute, iron deficiency may be beneficial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32554?source=see_link\">",
"     \"Restless legs syndrome\"",
"    </a>",
"    .) This was evaluated in a double-blind placebo-controlled randomized trial of 25 dialysis patients with severe restless legs syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14773/abstract/10\">",
"     10",
"    </a>",
"    ]. The placebo and iron-infusion groups had similar iron stores and",
"    <span class=\"nowrap\">",
"     hemoglobin/hematocrit",
"    </span>",
"    levels. Compared with placebo, infusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/46/21222?source=see_link\">",
"     iron dextran",
"    </a>",
"    resulted in a significant improvement in symptoms one and two weeks post-infusion, with a trend toward continued benefits at four weeks. However, among patients with restless legs syndrome who are iron replete, we are reluctant to administer additional iron because of the risk for iron overload. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37752?source=see_link\">",
"     \"Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38521?source=see_link\">",
"     \"Use of iron preparations in hemodialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to correcting anemia, other possible reported strategies for restless legs syndrome include decreasing exposure to agents that may exacerbate the syndrome, and administering levodopa or dopamine agonists [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14773/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24108764\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Uremic peripheral neuropathy is a distal, symmetrical, mixed sensorimotor neuropathy that occurs in patients with advanced renal disease. While peripheral polyneuropathy is an indication to initiate dialysis, it may also occur in patients who are already being adequately dialyzed. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The sensory symptoms generally occur before motor symptoms and include paresthesias, burning sensations, and pain. Sensory dysfunction may present as one of several distinct syndromes including the restless leg syndrome; the burning foot syndrome; and paradoxical heat sensation, in which the application of low temperature stimuli evokes the sensation of high temperature. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Sensory syndromes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Motor involvement reflects advanced disease and leads to muscle atrophy, myoclonus, and eventual paralysis. Complete recovery is unlikely once late stage motor involvement occurs. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Motor symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Electrophysiologic studies are the most sensitive way to detect uremic neuropathy and can also be used to monitor the course of disease once renal replacement therapy is initiated. Motor nerve conduction velocity is the most common parameter used to assess motor function. Sensory nerve conduction velocity of the sural nerve is even more sensitive in detecting early dysfunction, but is not as widely used. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathologic features of uremic polyneuropathy consist of demyelination and axonal degeneration, which are most severe distally. Demyelination of the posterior columns and other portions of the central nervous system has also been described. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pathology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Factors that may contribute to uremic neuropathy include decreased thiamine deficiency, transketolase activity, reduced plasma concentrations of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/25/9618?source=see_link\">",
"       biotin",
"      </a>",
"      and zinc, increased plasma concentrations of phenols and myoinositol, and hyperparathyroidism. The role of uremic toxins of medium molecular weight is unresolved. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pathology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment options include dialysis and renal transplantation. The institution of hemodialysis stabilizes or improves symptoms; the extent of recovery is directly related to the degree and extent of dysfunction prior to the initiation of dialysis. Renal transplantation more consistently improves neurologic symptoms than dialysis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14773/abstract/1\">",
"      Raskin NH, Fishman RA. Neurologic disorders in renal failure (first of two parts). N Engl J Med 1976; 294:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14773/abstract/2\">",
"      Fraser CL, Arieff AI. Nervous system complications in uremia. Ann Intern Med 1988; 109:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14773/abstract/3\">",
"      Krishnan AV, Kiernan MC. Uremic neuropathy: clinical features and new pathophysiological insights. Muscle Nerve 2007; 35:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14773/abstract/4\">",
"      Ropper AH. Accelerated neuropathy of renal failure. Arch Neurol 1993; 50:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14773/abstract/5\">",
"      Hanly PJ, Gabor JY, Chan C, Pierratos A. Daytime sleepiness in patients with CRF: impact of nocturnal hemodialysis. Am J Kidney Dis 2003; 41:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14773/abstract/6\">",
"      Thorp ML. Restless legs syndrome. Int J Artif Organs 2001; 24:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14773/abstract/7\">",
"      Kavanagh D, Siddiqui S, Geddes CC. Restless legs syndrome in patients on dialysis. Am J Kidney Dis 2004; 43:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14773/abstract/8\">",
"      Unruh ML, Levey AS, D'Ambrosio C, et al. Restless legs symptoms among incident dialysis patients: association with lower quality of life and shorter survival. Am J Kidney Dis 2004; 43:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14773/abstract/9\">",
"      Siddiqui, S, et al. Nephron Clin Pract 2005; 3:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14773/abstract/10\">",
"      Sloand JA, Shelly MA, Feigin A, et al. A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. Am J Kidney Dis 2004; 43:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14773/abstract/11\">",
"      Bolton CF, Laverty DA, Brown JD, et al. Critically ill polyneuropathy: electrophysiological studies and differentiation from Guillain-Barr&eacute; syndrome. J Neurol Neurosurg Psychiatry 1986; 49:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14773/abstract/12\">",
"      Hung SC, Hung SH, Tarng DC, et al. Chorea induced by thiamine deficiency in hemodialysis patients. Am J Kidney Dis 2001; 37:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14773/abstract/13\">",
"      Yosipovitch G, Yarnitsky D, Mermelstein V, et al. Paradoxical heat sensation in uremic polyneuropathy. Muscle Nerve 1995; 18:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14773/abstract/14\">",
"      Trojaborg W, Smith T, Jakobsen J, Rasmussen K. Cardiorespiratory reflexes, vibratory and thermal thresholds, sensory and motor conduction in diabetic patients with end-stage nephropathy. Acta Neurol Scand 1994; 90:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14773/abstract/15\">",
"      Makkar RK, Kochar DK. Somatosensory evoked potentials (SSEPs); sensory nerve conduction velocity (SNCV) and motor nerve conduction velocity (MNCV) in chronic renal failure. Electromyogr Clin Neurophysiol 1994; 34:295.",
"     </a>",
"    </li>",
"    <li>",
"     Bolton, CF, Young, GB. Uremic neuropathy. In: Neurological Complications of Renal Disease. Butterworth, Boston, 1990, pp. 76-107.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14773/abstract/17\">",
"      Nielsen VK. The peripheral nerve function in chronic renal failure. VI. The relationship betweeen sensory and motor nerve conduction and kidney function, azotemia, age, sex, and clinical neuropathy. Acta Med Scand 1973; 194:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14773/abstract/18\">",
"      Guolo M, Stella AM, Melito V, et al. Altered 5-aminolevulinic acid metabolism leading to pseudoporphyria in hemodialysed patients. Int J Biochem Cell Biol 1996; 28:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14773/abstract/19\">",
"      Tegn&eacute;r R, Lindholm B. Uremic polyneuropathy: different effects of hemodialysis and continuous ambulatory peritoneal dialysis. Acta Med Scand 1985; 218:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14773/abstract/20\">",
"      Lindsay RM, Bolton CF, Clark WF, Linton AL. The effect of alterations of uremic retention products upon platelet and peripheral nerve function. Clin Nephrol 1983; 19:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14773/abstract/21\">",
"      Bazzi C, Pagani C, Sorgato G, et al. Uremic polyneuropathy: a clinical and electrophysiological study in 135 short- and long-term hemodialyzed patients. Clin Nephrol 1991; 35:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14773/abstract/22\">",
"      Tattersall JE, Cramp M, Shannon M, et al. Rapid high-flux dialysis can cure uraemic peripheral neuropathy. Nephrol Dial Transplant 1992; 7:539.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1837 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-125.69.132.100-B0D0D57A02-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_27_14773=[""].join("\n");
var outline_f14_27_14773=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24108764\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Sensory syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Motor symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Restless legs syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24108764\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37752?source=related_link\">",
"      Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=related_link\">",
"      Kt/V and the adequacy of hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/7/1144?source=related_link\">",
"      Prescribed versus delivered dialysis: Importance of dialysis time",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32554?source=related_link\">",
"      Restless legs syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38521?source=related_link\">",
"      Use of iron preparations in hemodialysis patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_27_14774="Clinical trials of HIV antiretroviral therapy: Protease inhibitors versus non-nucleoside reverse transcriptase inhibitors";
var content_f14_27_14774=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical trials of HIV antiretroviral therapy: Protease inhibitors versus non-nucleoside reverse transcriptase inhibitors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/27/14774/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/27/14774/contributors\">",
"     Paul E Sax, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/27/14774/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/27/14774/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/27/14774/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/27/14774/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/27/14774/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been great interest in defining which combination therapy approach may be most beneficial for treatment-naive HIV-infected patients.",
"   </p>",
"   <p>",
"    This topic will discuss the major clinical trials that have been performed in the era of potent antiretroviral therapy (ART), which have compared regimens employing either non-nucleoside reverse transcriptase inhibitors (NNRTIs) versus protease inhibitors (PIs). Some of the studies were performed using older or currently unavailable formulations of antiviral agents, and hence have limited applicability to current practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiretroviral treatment (ART) regimens should have at least three active antiretroviral medications. In treatment-na&iuml;ve patients, recommended regimens should consist of two nucleoside reverse transcriptase inhibitors (NRTIs), with one of them being",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    , and either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted protease inhibitor (PI). Decision-making for the selection of antiretroviral therapy is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Abbreviations used",
"    </span>",
"    &nbsp;&mdash;&nbsp;The table shows commonly used abbreviations for the medications discussed in this topic (",
"    <a class=\"graphic graphic_table graphicRef60927 \" href=\"UTD.htm?24/25/24989\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2710981\">",
"    <span class=\"h2\">",
"     Pharmacokinetic boosting with ritonavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    are often used in conjunction with a PI to raise serum concentrations of the parent drug. Use of low-dose ritonavir in a \"boosted\" regimen is often indicated with a small \"r\" (eg,",
"    <span class=\"nowrap\">",
"     \"lopinavir/r\"",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     LPV/r).",
"    </span>",
"    Pharmacokinetic boosting is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=see_link\">",
"     \"HIV protease inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     STUDIES IN TREATMENT-NAIVE PATIENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Nelfinavir versus efavirenz (ACTG 384)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    1250 mg twice daily with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    600 mg daily in 620 treatment-naive patients who received an NRTI backbone of either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    (ZDV) 300 mg twice daily plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    (3TC) 150 mg twice daily or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    (ddI) 400 mg daily plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    (d4T) 40 mg twice daily [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14774/abstract/1\">",
"     1",
"    </a>",
"    ]. Treated patients, who failed their first assigned regimen (because of toxicity or virologic failure), were reassigned to the alternate regimen, and the time to failure of the second regimen was the primary end point of the trial.",
"   </p>",
"   <p>",
"    Compared with patients initially treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    , patients starting with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    (and a",
"    <span class=\"nowrap\">",
"     ZDV/3TC",
"    </span>",
"    backbone) were less likely to reach the primary end point (hazard ratio [HR] 0.71, 95% CI 0.48-1.06). The risk of failure of the first regimen was also lower in patients treated with efavirenz who received",
"    <span class=\"nowrap\">",
"     ZDV/3TC",
"    </span>",
"    (HR 0.39, 95% CI 0.24-0.64) but was not significantly lower in those who received",
"    <span class=\"nowrap\">",
"     ddI/d4T.",
"    </span>",
"   </p>",
"   <p>",
"    This study established the two NRTIs plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    combination as the gold standard for HIV treatment against which other regimens would be compared for many years to come.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Atazanavir versus efavirenz",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    400 mg daily with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    600 mg daily in 810 treatment-naive patients who also received open label twice-daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    300 mg plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    150 mg [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14774/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The proportions of patients achieving an HIV viral load below 400",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    at week 48 were similar in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    (70 versus 64 percent) as were the proportions achieving a viral load below 50",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    (32 versus 37 percent). Among patients who completed 48 weeks of treatment (an \"as-treated\" analysis), the proportion achieving a viral load below 50",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    was also similar (44 versus 51 percent). The low rates of viral suppression seen in both arms of the study were apparently related to laboratory problems with the type of preservative used for the samples.",
"   </p>",
"   <p>",
"    The overall frequency of adverse events was similar in the two groups, with rash and dizziness occurring more frequently with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    , and jaundice and scleral icterus occurring more frequently with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    . Serious adverse events occurred in 10 percent of each group.",
"   </p>",
"   <p>",
"    Overall,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    treatment was associated with a more favorable lipid profile with significant differences in the change from baseline in total cholesterol (2 versus 21 percent), LDL-cholesterol (1 versus 18 percent) and triglycerides (-9 versus 23 percent); the increase in HDL-cholesterol was smaller with atazanavir (13 versus 24 percent). Glucose levels were not significantly changed from baseline in either group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Saquinavir versus efavirenz (FOCUS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;FOCUS was a randomized trial that compared a boosted",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    -based regimen",
"    <span class=\"nowrap\">",
"     (saquinavir/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"      ritonavir",
"     </a>",
"    </span>",
"    1600",
"    <span class=\"nowrap\">",
"     mg/100",
"    </span>",
"    mg) daily with an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    -based regimen in 152 treatment-naive patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14774/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a preliminary report, more patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    had a viral load below 50",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    at 48 weeks (71 versus 51 percent). The use of the soft-gel formulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    and the high pill burden (which required eight capsules daily) contributed to high rates of gastrointestinal side effects. This formulation is no longer available, having been replaced by saquinavir 500 mg hard-gel capsules.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Amprenavir versus efavirenz (CLASS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;CLASS was a randomized trial that compared a boosted amprenavir-based regimen with an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    -based regimen (as well as a triple NRTI regimen) in 291 treatment-naive patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14774/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a preliminary report, fewer patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    experienced first virologic failure than patients in the other arms of the study. Amprenavir is no longer available, having been replaced by its better-tolerated pro-drug,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/11/44217?source=see_link\">",
"     fosamprenavir",
"    </a>",
"    . As a result, the applicability of this study to current practice is limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Nelfinavir versus nevirapine (COMBINE)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    1250 mg twice daily with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    200 mg twice daily in 142 treatment-naive patients who also received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    300 mg twice daily plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    150 mg twice daily [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14774/abstract/5\">",
"     5",
"    </a>",
"    ]. After 12 months, more patients treated with nevirapine had a viral load below 20",
"    <span class=\"nowrap\">",
"     copies/mL,",
"    </span>",
"    although the results did not achieve statistical significance (65 versus 50 percent) due to the relatively small sample size of the study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     PI versus NNRTI-based ART (FIRST)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Between 1999 and 2002, 1397 antiretroviral therapy-naive patients at 80 research sites were randomly assigned to a PI, NNRTI, or a PI plus an NNRTI treatment regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14774/abstract/6\">",
"     6",
"    </a>",
"    ]. All patients received two nucleoside analogs as part of their combination ART.",
"   </p>",
"   <p>",
"    Over a median follow-up of five years, there was no difference in immunologic or clinical outcomes (AIDS-defining event or death) between an initial PI-based and an NNRTI-based regimen. Furthermore, a three-class strategy did not offer any additional clinical benefit and was associated with more adverse events.",
"   </p>",
"   <p>",
"    The comparable clinical outcomes with a PI versus an NNRTI strategy remained valid even in patient subgroups with an HIV RNA level &gt;100,000",
"    <span class=\"nowrap\">",
"     copies/mL.",
"    </span>",
"    However, most of the patients in the PI arm were taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    rather than a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted protease inhibitor, which is now more commonly used.",
"   </p>",
"   <p>",
"    These results are comparable to the INITIO and ACTG 384 trials, which had a similar study design; all of these trials demonstrated greater antiviral activity in the two NRTI +",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    arm compared to the two NRTI + PI arm and no additional benefit of using all three drug classes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33682?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Three versus four-drug regimens\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     PI versus NNRTI-based strategy (ACTG 5142, ACTG 5202, ALTAIR)",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the most important trials to date that addressed the question of which drug class to initiate in treatment-naive patients was ACTG 5142. The ACTG 5142 trial was a multicenter open-label study of 753 treatment-naive patients who were randomly assigned to receive",
"    <span class=\"nowrap\">",
"     lopinavir/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"      ritonavir",
"     </a>",
"    </span>",
"    plus two nucleoside analogs (NRTIs), or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    plus two NAs, or efavirenz plus",
"    <span class=\"nowrap\">",
"     lopinavir/ritonavir",
"    </span>",
"    alone (a nucleoside-sparing arm) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14774/abstract/7\">",
"     7",
"    </a>",
"    ]. The median CD4 count was 191",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    and the median HIV RNA level was 4.8 log(10)",
"    <span class=\"nowrap\">",
"     copies/mL.",
"    </span>",
"   </p>",
"   <p>",
"    At",
"    96 weeks, the following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Viral suppression (&lt;50",
"      <span class=\"nowrap\">",
"       copies/mL)",
"      </span>",
"      was achieved in a significantly greater proportion of patients on the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      arm (89 percent) compared with either the",
"      <span class=\"nowrap\">",
"       lopinavir/",
"       <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"        ritonavir",
"       </a>",
"      </span>",
"      arm (77 percent) or the NRTI-sparing arm (83 percent).",
"     </li>",
"     <li>",
"      NNRTI resistance was more frequent in the NRTI-sparing arm (66 percent) versus the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      arm (43 percent). Compared with the efavirenz arm, fewer patients in the",
"      <span class=\"nowrap\">",
"       lopinavir/",
"       <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"        ritonavir",
"       </a>",
"      </span>",
"      arm had mutations associated with resistance to two drug classes (1 versus 26 percent) or the K65R substitution (0 versus 7 percent).",
"     </li>",
"     <li>",
"      The median increase in CD4 cells was significantly greater in the",
"      <span class=\"nowrap\">",
"       lopinavir/",
"       <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"        ritonavir",
"       </a>",
"      </span>",
"      arm (287",
"      <span class=\"nowrap\">",
"       cells/microL)",
"      </span>",
"      and the NRTI-sparing groups (273",
"      <span class=\"nowrap\">",
"       cells/microL)",
"      </span>",
"      compared with the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      arm (230",
"      <span class=\"nowrap\">",
"       cells/microL).",
"      </span>",
"     </li>",
"     <li>",
"      The proportion of patients with at least one new grade 3 or 4 laboratory event was higher in the NRTI-sparing group than either of the other two groups, mainly due to elevations in fasting triglycerides.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This trial illustrates different advantages for NNRTI- or PI-based strategies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although virologic efficacy was greater in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      arm, patterns in the development of drug resistance favored the",
"      <span class=\"nowrap\">",
"       lopinavir/",
"       <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"        ritonavir",
"       </a>",
"      </span>",
"      arm.",
"     </li>",
"     <li>",
"      Failure of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      was associated with the emergence of NNRTI resistance, whereas failure of",
"      <span class=\"nowrap\">",
"       lopinavir/",
"       <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"        ritonavir",
"       </a>",
"      </span>",
"      was not associated with",
"      <span class=\"nowrap\">",
"       lopinavir/ritonavir",
"      </span>",
"      resistance mutations.",
"     </li>",
"     <li>",
"      The virologic efficacy of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      plus",
"      <span class=\"nowrap\">",
"       lopinavir/",
"       <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"        ritonavir",
"       </a>",
"      </span>",
"      supports its potential use in patients with intolerance to NRTIs. However, the frequency of lipid abnormalities and NNRTI resistance mutations suggests that the NRTI-sparing regimen should NOT be routinely employed. Other NRTI-sparing strategies employing boosted PIs plus either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"       maraviroc",
"      </a>",
"      are being studied.",
"     </li>",
"     <li>",
"      A second large clinical trial, ACTG A5202, compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      -boosted",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      <span class=\"nowrap\">",
"       (ATV/r)",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      with either",
"      <span class=\"nowrap\">",
"       ABC/3TC",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       TDF/FTC",
"      </span>",
"      in 1857 treatment-na&iuml;ve study subjects [",
"      <a class=\"abstract\" href=\"UTD.htm?14/27/14774/abstract/8\">",
"       8",
"      </a>",
"      ]. The patients and investigators were only blinded to the NRTI assignments. At the end of 96 weeks, time to virologic failure was not significantly different between the efavirenz and boosted atazanavir arms regardless of the NRTI used, with more than 80 percent of subjects remaining free of viral failure. As with A5142, if virologic rebound occurred, resistance was more common in those receiving efavirenz than boosted atazanavir. Overall, this is the first large comparative trial to demonstrate comparable antiviral efficacy of a boosted PI to efavirenz, possibly due to the better tolerability of once-daily boosted atazanavir compared with earlier PIs. A smaller comparative trial found similar results [",
"      <a class=\"abstract\" href=\"UTD.htm?14/27/14774/abstract/9\">",
"       9",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple studies have demonstrated that the combination of two nucleoside reverse transcriptase inhibitors (NRTIs) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      is at least, if not more effective, in achieving viral suppression than two NRTIs plus a protease inhibitor (PI). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Studies in treatment-naive patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most recent comparison between",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      -boosted",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      , A5202, showed comparable antiviral activity of the NNRTI and boosted PI approach.",
"     </li>",
"     <li>",
"      Despite the antiviral advantages of the 2 NRTI +",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      regimen, ACTG 5142 and A5202 demonstrated that virologic failure on this regimen is more likely to lead to resistance than the comparator arm of two NRTIs plus",
"      <span class=\"nowrap\">",
"       lopinavir/",
"       <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"        ritonavir",
"       </a>",
"       .",
"      </span>",
"      In addition, in A5142,",
"      <span class=\"nowrap\">",
"       lopinavir/ritonavir-treated",
"      </span>",
"      patients had a better overall CD4 cell count response than those receiving efavirenz. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'PI versus NNRTI-based strategy (ACTG 5142, ACTG 5202, ALTAIR)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The results of ACTG 5142 and ACTG 5202 strongly support the use of two NRTIs plus either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      or a boosted PI as initial therapy for HIV-infected patients.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14774/abstract/1\">",
"      Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349:2293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14774/abstract/2\">",
"      Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004; 36:1011.",
"     </a>",
"    </li>",
"    <li>",
"     Montaner JS, Saag MS, Barylski C, et al. FOCUS study: Saquinavir QD regimen versus efavirenz QD regimen 48 week analysis in HIV infected patients. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 2002, San Diego.",
"    </li>",
"    <li>",
"     Bartlett JA, Johnson J, Herrera G, et al. Initial therapy with abacavir+lamivudine (ABC+3TC) combined with efavirenz (NNRTI), amprenavir/ritonavir (PI) or stavudine (NRTI): ESS40001 (CLASS). XVth International AIDS Conference, July 2004, Bangkok.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14774/abstract/5\">",
"      Podzamczer D, Ferrer E, Consiglio E, et al. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). Antivir Ther 2002; 7:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14774/abstract/6\">",
"      MacArthur RD, Novak RM, Peng G, et al. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial. Lancet 2006; 368:2125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14774/abstract/7\">",
"      Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358:2095.",
"     </a>",
"    </li>",
"    <li>",
"     file://retroconference.org/2010/Abstracts/39789.htm (Accessed on November 27, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14774/abstract/9\">",
"      Puls RL, Srasuebkul P, Petoumenos K, et al. Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study. Clin Infect Dis 2010; 51:855.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3793 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-6A22C7A760-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_27_14774=[""].join("\n");
var outline_f14_27_14774=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Abbreviations used",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2710981\">",
"      Pharmacokinetic boosting with ritonavir",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      STUDIES IN TREATMENT-NAIVE PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Nelfinavir versus efavirenz (ACTG 384)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Atazanavir versus efavirenz",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Saquinavir versus efavirenz (FOCUS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Amprenavir versus efavirenz (CLASS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Nelfinavir versus nevirapine (COMBINE)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PI versus NNRTI-based ART (FIRST)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PI versus NNRTI-based strategy (ACTG 5142, ACTG 5202, ALTAIR)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3793\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3793|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/25/24989\" title=\"table 1\">",
"      Antiretroviral drugs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33682?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Three versus four-drug regimens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=related_link\">",
"      HIV protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_27_14775="Pseudomonas aeruginosa bacteremia and endocarditis";
var content_f14_27_14775=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pseudomonas aeruginosa bacteremia and endocarditis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/27/14775/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/27/14775/contributors\">",
"     Souha S Kanj, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/27/14775/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/27/14775/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/27/14775/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/27/14775/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/27/14775/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/27/14775/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudomonas aeruginosa is one of the most commonly considered gram-negative aerobic bacilli in the differential diagnosis of a number of probable gram-negative infections. This organism is frequently feared because it causes severe nosocomial infections, especially in immunocompromised hosts, and is often antibiotic resistant, complicating the choice of therapy.",
"   </p>",
"   <p>",
"    P. aeruginosa is a non-fermentative gram-negative aerobic rod that grows easily on a variety of media. A characteristic sweet grape like odor, the elaboration of green pigment, and its oxidase-positive property are helpful in confirming its presence on culture plates. Occasionally, identification by laboratory personnel may be delayed because isolates lack pigments or produce unusual characteristics, such as a \"rotten-potato\" odor [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14775/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, and treatment of P. aeruginosa bacteremia and endocarditis will be reviewed here. The clinical manifestations and management of other P. aeruginosa infections and the epidemiology and pathogenesis of infection with this organism are discussed separately. (See related topics).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACTEREMIA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;P. aeruginosa infection is a nosocomial problem worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14775/abstract/2-7\">",
"     2-7",
"    </a>",
"    ]. In a prospective analysis from the SCOPE (Surveillance and Control of Pathogens of Epidemiologic Importance) database of 24,179 nosocomial bloodstream infections occurring in 49 hospitals in the United States between 1995 to 2002, Pseudomonas species accounted for 4 percent of cases and were the third leading cause of gram-negative infections [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14775/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37464?source=see_link\">",
"     \"Epidemiology, pathogenesis, and microbiology of intravascular catheter infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Risk factors for P. aeruginosa bacteremia include [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14775/abstract/4,7-13\">",
"     4,7-13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Neutropenia or other immunodeficiency (eg, hematologic malignancy, solid organ or bone marrow transplantation, or HIV infection)",
"     </li>",
"     <li>",
"      Advanced age",
"     </li>",
"     <li>",
"      Pancreatobiliary tract disease",
"     </li>",
"     <li>",
"      Severe burns",
"     </li>",
"     <li>",
"      Indwelling central venous or urinary catheter",
"     </li>",
"     <li>",
"      Antimicrobial therapy within the last 30 days",
"     </li>",
"     <li>",
"      Traumatic wounds that have been contaminated with fresh water",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nosocomial P. aeruginosa bacteremia may result from primary infection in the lungs, biliary and gastrointestinal tract, urinary tract, skin and soft tissues, or from infected intravascular catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14775/abstract/5,14,15\">",
"     5,14,15",
"    </a>",
"    ]. The source of the bacteremia is unknown in up to 40 percent of cases.",
"   </p>",
"   <p>",
"    Pancreatobiliary tract disease is an important risk factor for bacteremia, independent of underlying malignancy or immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14775/abstract/14\">",
"     14",
"    </a>",
"    ]. Pancreatobiliary sources and complications from endoscopic retrograde cholangiopancreatography (ERCP) appear to be increasing in frequency as the cause of P. aeruginosa bacteremia in many regions. Clusters of P. aeruginosa bacteremias after ERCP have been traced to inadequate cleaning or disinfection of endoscopes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14775/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among immunocompetent patients, P. aeruginosa bacteremia is largely seen in patients with indwelling urinary and central venous catheters and following traumatic or surgical wound infections [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14775/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;P. aeruginosa bacteremia does not differ clinically from bacteremia due to other gram-negative bacilli, all of which contain endotoxin, the initiator of shock in these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5449?source=see_link\">",
"     \"Pathophysiology of sepsis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Septic shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacteremic patients typically present with fever, tachycardia, and tachypnea. Disorientation, hypotension, and respiratory failure (due to either Pseudomonas pneumonia or acute respiratory distress syndrome [ARDS]) are other distressingly common complications, especially in immunocompromised or debilitated patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Ecthyma gangrenosum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although it is usually impossible to distinguish patients with P. aeruginosa bacteremia from patients with bacteremia due to other gram-negative rods, patients with P. aeruginosa infection are more likely to have a fatal outcome and to develop ecthyma gangrenosum. The lesions of ecthyma gangrenosum (",
"    <a class=\"graphic graphic_picture graphicRef80582 \" href=\"UTD.htm?26/43/27314\">",
"     picture 1",
"    </a>",
"    ) involve the skin or mucous membranes, beginning as a small area of edema and quickly evolving into painless nodular lesions with central hemorrhage, ulceration, and necrosis. Ecthyma gangrenosum results from perivascular bacterial invasion of the media and adventitia of arteries and veins with secondary ischemic necrosis. Ecthyma lesions typically progress rapidly (within 12 to 18 hours). Lesions may be single or multiple; in the latter case, they may be in different stages of development at any given point in time.",
"   </p>",
"   <p>",
"    Although ecthyma gangrenosum is not pathognomonic of P. aeruginosa infection, the presence of these lesions should immediately raise the high probability that P. aeruginosa is the causative organism. Other skin lesions that may occasionally accompany pseudomonal bacteremia include: diffuse maculopapular lesions; painful cluster of small vesicles or pustules; flat sharply demarcated areas of cellulitis that may initially mimic erysipelas and become necrotic with time; and metastatic soft tissue abscesses that may appear on the extremities and fingertips [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14775/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following principles apply to the treatment of P. aeruginosa bacteremia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Delayed therapy correlates with increased mortality.",
"     </li>",
"     <li>",
"      All infected catheters should be removed, and, whenever possible, abscesses or obstructions should be drained or removed.",
"     </li>",
"     <li>",
"      Combination therapy is indicated in certain high risk patients and in severe infections.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A complete discussion of treatment regimens is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39528?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment of Pseudomonas aeruginosa infections\", section on 'Bacteremia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacteremia due to P. aeruginosa is associated with a high mortality rate compared with bacteremia due to other gram-negative bacilli as well as gram-positive organisms. One study, which prospectively compared 314 patients with bacteremia due to P. aeruginosa or S. aureus, found that mortality was significantly higher with P. aeruginosa than with either methicillin-susceptible S. aureus (MSSA) or methicillin-resistant S. aureus (MRSA) (30.6 percent, 16.2 percent, and 13.5 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14775/abstract/20\">",
"     20",
"    </a>",
"    ]. Mortality is especially high in neutropenic patients and in patients who present with or develop septic shock. In a study of 133 episodes of P. aeruginosa bacteremia, a stepwise logistic regression analysis identified four variables as independently influencing outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14775/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Development of septic shock",
"     </li>",
"     <li>",
"      Granulocyte count",
"      <span class=\"nowrap\">",
"       &lt;500/mm3",
"      </span>",
"     </li>",
"     <li>",
"      Inappropriate antibiotic therapy",
"     </li>",
"     <li>",
"      Development of septic metastasis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, a retrospective analysis of 136 patients with P. aeruginosa bacteremia found that the 30-day mortality rate was 39 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14775/abstract/22\">",
"     22",
"    </a>",
"    ]. Risk factors for mortality in this study included severe sepsis, pneumonia, delay in starting effective antimicrobial therapy, and an increasing APACHE II score.",
"   </p>",
"   <p>",
"    Other factors that may negatively impact prognosis are the presence of drug resistance and co-infection with other bacteria. Two studies found that strains of P. aeruginosa that produce metallo-beta-lactamases or specific (PER-1) extended spectrum beta-lactamases cause unusually high mortality rates when present in the bloodstream [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14775/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. In a prospective multicenter study of 632 cases of P. aeruginosa bacteremia, carbapenem resistance (n = 145) was not associated with higher mortality overall (35 versus 27 percent with susceptible strains); however, in a subgroup analysis, higher 30-day mortality rates were noted among patients with few comorbidities when carbapenem resistance was present (adjusted OR 6 to 10) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14775/abstract/25\">",
"     25",
"    </a>",
"    ]. Another study showed that in patients with pseudomonas infection, polymicrobial bacteremia was associated with a worse clinical outcome and a higher incidence of shock than monomicrobial bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14775/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The choice and timing of antibiotic therapy is particularly crucial. As an example, in one study of 410 episodes of P. aeruginosa bacteremia, cure was substantially higher in patients receiving appropriate antibiotics than in those who did not (67 versus 14 percent), and a one- to two-day delay in administering appropriate antibiotics reduced the cure rate from 74 to 46 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14775/abstract/27\">",
"     27",
"    </a>",
"    ]. In one prospective ICU study, inadequate antimicrobial therapy was statistically associated with a higher mortality rate (62 versus 28 percent, RR 2.18, 95 percent CI 5.09-9.24, p&lt;0.001) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14775/abstract/28\">",
"     28",
"    </a>",
"    ]. Approximately 10 percent of patients in this study had P. aeruginosa bacteremia.",
"   </p>",
"   <p>",
"    Other studies have shown that the prognosis of P. aeruginosa bacteremia is closely related to the underlying condition of the host and the primary site of infection. In a study of 100 episodes of P. aeruginosa bacteremia, survival directly correlated with underlying disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14775/abstract/29\">",
"     29",
"    </a>",
"    ]. Thirty-six of 47 patients (55 percent) with nonfatal underlying conditions survived, compared with 2 of 13 (15 percent) and 16 of 64 (25 percent) with rapidly fatal and ultimately fatal underlying conditions, respectively. Mortality is also usually higher when the bacteremia accompanies a pulmonary infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14775/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognosis of P. aeruginosa bacteremia in neutropenic patients with hematologic malignancies has actually improved in recent years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14775/abstract/31\">",
"     31",
"    </a>",
"    ]. One retrospective study showed an improved prognosis of P. aeruginosa bacteremia in the years 1992 to 1996 compared with 1976 to 1982 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14775/abstract/32\">",
"     32",
"    </a>",
"    ]. This improvement was due mainly to changes in the management of the infection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      More frequent use of new anti-pseudomonal beta-lactams and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      instead of aminoglycosides as monotherapy.",
"     </li>",
"     <li>",
"      Prompt removal of catheters.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a retrospective study evaluating the morbidity of P. aeruginosa bacteremia, advanced age and elevated Sequential Organ Failure Assessment (SOFA) scores (a measure of baseline illness severity) were strong predictors of morbidity and in-hospital mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14775/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of patients with hematologic malignancies who had Pseudomonas infections, hypophosphatemia, hypoproteinemia, and high serum lactate were associated with an increased risk of septic shock on multivariate analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14775/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ENDOCARDITIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H296144973\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infective endocarditis (IE) due to P. aeruginosa is uncommon, but when it occurs, it is strongly associated with injection drug use (IDU),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prosthetic heart valves [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14775/abstract/35\">",
"     35",
"    </a>",
"    ] and pacemakers. More than 90 percent of cases of IE due to P. aeruginosa have been reported in IDU, and most patients had no previous structural heart disease. P. aeruginosa IE tends to occur in specific geographic locations; epidemics of this infection have been described in IDU, mainly abusers of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/48/29446?source=see_link\">",
"     pentazocine",
"    </a>",
"    and tripelennamine, presumably associated with mixing of drugs in contaminated water [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14775/abstract/36\">",
"     36",
"    </a>",
"    ]. P. aeruginosa is also an occasional cause of nosocomial endocarditis, accounting for 10 percent of cases in one small ICU series [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14775/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since this infection is closely associated with IDU, it is not surprising that the most frequently involved valve is the tricuspid valve, but biventricular and multiple valve involvement also occur. In a study of 34 cases from one center, 13 had isolated involvement of the tricuspid valve and an additional case had tricuspid and pulmonic valve infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14775/abstract/38\">",
"     38",
"    </a>",
"    ]. Patients with tricuspid valve infection typically have a less fulminant course and better prognosis than patients with left-sided valvular involvement. In one study, 20 of 25 patients with right-sided infection recovered with medical or combined",
"    <span class=\"nowrap\">",
"     medical/surgical",
"    </span>",
"    therapy compared with only three of nine patients with left-sided infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14775/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations of IE are similar whether due to P. aeruginosa or other organisms; however, since tricuspid infection is common, many patients present with pulmonary manifestations, including cough, chest pain, and hemoptysis. Such patients often have multiple discrete lung lesions that may progress to cavitation. Patients with left-sided valvular infections often develop fulminant or rapidly progressive symptoms that are due to either congestive heart failure or embolism of large or medium-sized arteries. Ring and annular abscesses are also frequent complications [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14775/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of tricuspid endocarditis due to P. aeruginosa can sometimes be difficult since bacteremia due to this organism is more common than IE, and patients with prosthetic heart valves can have P. aeruginosa bacteremia in association with a urinary tract or wound infection. In such cases, echocardiography and application of the Duke Criteria for endocarditis often resolve the diagnostic question of whether or not endocarditis is present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=see_link\">",
"     \"Diagnostic approach to infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of P. aeruginosa IE is hindered by the fact that beta-lactam antibiotics have a slow onset of bactericidal activity against the organism, lack a postantibiotic effect, and rapidly induce the development of resistance. Thus, treatment of P. aeruginosa IE usually necessitates the combination of antibiotics and surgery to achieve cure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14775/abstract/3\">",
"     3",
"    </a>",
"    ]. A complete discussion of treatment regimens is presented separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39528?source=see_link&amp;anchor=H21#H21\">",
"     \"Treatment of Pseudomonas aeruginosa infections\", section on 'Endocarditis'",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;P. aeruginosa endocarditis is associated with a poor outcome. In one study in patients with S. aureus and P. aeruginosa bacteremia, endocarditis was found to be an independent determinant of hospital mortality (OR 4.62; 95 percent CI 2.45-8.73) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14775/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with left-sided IE due to P. aeruginosa, the prognosis for medical therapy is worse than for combined medical and surgical therapy. Early valve replacement has been shown to improve prognosis and is indicated in cases refractory to medical treatment and in complicated cases with hemodynamic instability. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22297?source=see_link\">",
"     \"Surgery for native valve endocarditis\"",
"    </a>",
"    .) For this reason, we routinely obtain early surgical consultation in all cases of P. aeruginosa endocarditis. When splenic abscesses complicate P. aeruginosa IE, splenectomy should be performed prior to valve replacement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H296145128\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudomonas aeruginosa is one of the most commonly considered gram-negative aerobic bacilli in the differential diagnosis of a number of probable gram-negative infections. This organism is frequently feared because it causes severe nosocomial infections, especially in immunocompromised hosts, and is often antibiotic resistant, complicating the choice of therapy. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H296145101\">",
"    <span class=\"h2\">",
"     Bacteremia",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Risk factors for P. aeruginosa bacteremia include neutropenia or other immunodeficiency (eg, hematologic malignancy, solid organ or bone marrow transplantation, or HIV infection), advanced age, pancreatobiliary tract disease, severe burns, an indwelling central venous or urinary catheter, antimicrobial therapy within the last 30 days, and traumatic wounds that have been contaminated with fresh water. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nosocomial P. aeruginosa bacteremia may result from primary infection in the lungs, biliary and gastrointestinal tract, urinary tract, skin and soft tissues or from infected intravascular catheters. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bacteremic patients typically present with fever, tachycardia, and tachypnea. Disorientation, hypotension, and respiratory failure due to either Pseudomonas pneumonia or acute respiratory distress syndrome are other distressingly common complications, especially in immunocompromised or debilitated patients. Although it is usually impossible to distinguish patients with P. aeruginosa bacteremia from patients with bacteremia due to other gram-negative rods, patients with P. aeruginosa infection are more likely to have a fatal outcome and to develop ecthyma gangrenosum. The lesions of ecthyma gangrenosum (",
"      <a class=\"graphic graphic_picture graphicRef80582 \" href=\"UTD.htm?26/43/27314\">",
"       picture 1",
"      </a>",
"      ) involve the skin or mucous membranes, beginning as a small area of edema and quickly evolving into painless nodular lesions with central hemorrhage, ulceration and necrosis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The following principles apply to the treatment of P. aeruginosa bacteremia:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Delayed therapy correlates with increased mortality.",
"     </li>",
"     <li>",
"      All infected catheters should be removed, and, whenever possible, abscesses or obstructions should be drained or removed.",
"     </li>",
"     <li>",
"      Combination therapy is indicated in certain high-risk patients and in severe infections.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A complete discussion of treatment regimens is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39528?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment of Pseudomonas aeruginosa infections\", section on 'Bacteremia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bacteremia due to P. aeruginosa is associated with a high mortality rate compared with bacteremia due to other gram-negative bacilli as well as gram-positive organisms. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H296145136\">",
"    <span class=\"h2\">",
"     Endocarditis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infective endocarditis (IE) due to P. aeruginosa is uncommon, but when it occurs, it is strongly associated with injection drug use (IDU),",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      prosthetic heart valves and pacemakers. (See",
"      <a class=\"local\" href=\"#H296144973\">",
"       'Epidemiology'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Since this infection is closely associated with IDU, it is not surprising that the most frequently involved valve is the tricuspid valve, but biventricular and multiple valve involvement also occur. The clinical manifestations of IE are similar whether due to P. aeruginosa or other organisms; however, since tricuspid infection is common, many patients present with pulmonary manifestations, including cough, chest pain, and hemoptysis. Patients with left-sided valvular infections often develop fulminant or rapidly progressive symptoms that are due to either congestive heart failure or embolism of large or medium-sized arteries. Ring and annular abscesses are also frequent complications. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of tricuspid endocarditis due to P. aeruginosa can sometimes be difficult since bacteremia due to this organism is more common than IE, and patients with prosthetic heart valves can have P. aeruginosa bacteremia in association with a urinary tract or wound infection. In such cases, echocardiography and application of the Duke Criteria for endocarditis often resolve the diagnostic question of whether or not endocarditis is present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=see_link\">",
"       \"Diagnostic approach to infective endocarditis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of P. aeruginosa IE usually necessitates the combination of antibiotics and surgery to achieve cure. A complete discussion of treatment regimens is presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39528?source=see_link&amp;anchor=H21#H21\">",
"       \"Treatment of Pseudomonas aeruginosa infections\", section on 'Endocarditis'",
"      </a>",
"      .).",
"     </li>",
"     <li>",
"      P. aeruginosa endocarditis is associated with a poor outcome. In patients with left-sided IE due to P. aeruginosa, the prognosis for medical therapy is worse than for combined medical and surgical therapy. Early valve replacement has been shown to improve prognosis and is indicated in cases refractory to medical treatment and in complicated cases with hemodynamic instability. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14775/abstract/1\">",
"      Labarca JA, Pegues DA, Wagar EA, et al. Something's rotten: a nosocomial outbreak of malodorous Pseudomonas aeruginosa. Clin Infect Dis 1998; 26:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14775/abstract/2\">",
"      Al-Hasan MN, Wilson JW, Lahr BD, et al. Incidence of Pseudomonas aeruginosa bacteremia: a population-based study. Am J Med 2008; 121:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14775/abstract/3\">",
"      National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986-April 1996, issued May 1996. A report from the National Nosocomial Infections Surveillance (NNIS) System. Am J Infect Control 1996; 24:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14775/abstract/4\">",
"      Vidal F, Mensa J, Almela M, et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch Intern Med 1996; 156:2121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14775/abstract/5\">",
"      Sifuentes-Osornio J, Gonzalez R, Ponce-de-Leon A, Guerrero ML. Epidemiology and prognosis of Pseudomonas aeruginosa bacteremia in a tertiary care center. Rev Invest Clin 1998; 50:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14775/abstract/6\">",
"      Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14775/abstract/7\">",
"      Chatzinikolaou I, Abi-Said D, Bodey GP, et al. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: Retrospective analysis of 245 episodes. Arch Intern Med 2000; 160:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14775/abstract/8\">",
"      Schechner V, Nobre V, Kaye KS, et al. Gram-negative bacteremia upon hospital admission: when should Pseudomonas aeruginosa be suspected? Clin Infect Dis 2009; 48:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14775/abstract/9\">",
"      Mendelson MH, Gurtman A, Szabo S, et al. Pseudomonas aeruginosa bacteremia in patients with AIDS. Clin Infect Dis 1994; 18:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14775/abstract/10\">",
"      Shepp DH, Tang IT, Ramundo MB, Kaplan MK. Serious Pseudomonas aeruginosa infection in AIDS. J Acquir Immune Defic Syndr 1994; 7:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14775/abstract/11\">",
"      Leigh L, Stoll BJ, Rahman M, McGowan J Jr. Pseudomonas aeruginosa infection in very low birth weight infants: a case-control study. Pediatr Infect Dis J 1995; 14:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14775/abstract/12\">",
"      Dropulic LK, Leslie JM, Eldred LJ, et al. Clinical manifestations and risk factors of Pseudomonas aeruginosa infection in patients with AIDS. J Infect Dis 1995; 171:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14775/abstract/13\">",
"      Sorvillo F, Beall G, Turner PA, et al. Incidence and determinants of Pseudomonas aeruginosa infection among persons with HIV: association with hospital exposure. Am J Infect Control 2001; 29:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14775/abstract/14\">",
"      Chen SC, Lawrence RH, Byth K, Sorrell TC. Pseudomonas aeruginosa bacteraemia. Is pancreatobiliary disease a risk factor? Med J Aust 1993; 159:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14775/abstract/15\">",
"      Centers for Disease Control and Prevention (CDC). Pseudomonas aeruginosa infections associated with transrectal ultrasound-guided prostate biopsies--Georgia, 2005. MMWR Morb Mortal Wkly Rep 2006; 55:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14775/abstract/16\">",
"      Classen DC, Jacobson JA, Burke JP, et al. Serious Pseudomonas infections associated with endoscopic retrograde cholangiopancreatography. Am J Med 1988; 84:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14775/abstract/17\">",
"      Healey LA, Backes MB. Nitritoid reactions and angiotension-converting-enzyme inhibitors. N Engl J Med 1989; 321:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14775/abstract/18\">",
"      Roberts R, Tarpay MM, Marks MI, Nitschke R. Erysipelaslike lesions and hyperesthesia as manifestations of Pseudomonas aeruginosa sepsis. JAMA 1982; 248:2156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14775/abstract/19\">",
"      FORKNER CE Jr, FREI E 3rd, EDGCOMB JH, UTZ JP. Pseudomonas septicemia; observations on twenty-three cases. Am J Med 1958; 25:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14775/abstract/20\">",
"      Osmon S, Ward S, Fraser VJ, Kollef MH. Hospital mortality for patients with bacteremia due to Staphylococcus aureus or Pseudomonas aeruginosa. Chest 2004; 125:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14775/abstract/21\">",
"      Bisbe J, Gatell JM, Puig J, et al. Pseudomonas aeruginosa bacteremia: univariate and multivariate analyses of factors influencing the prognosis in 133 episodes. Rev Infect Dis 1988; 10:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14775/abstract/22\">",
"      Kang CI, Kim SH, Kim HB, et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 2003; 37:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14775/abstract/23\">",
"      Marra AR, Pereira CA, Gales AC, et al. Bloodstream infections with metallo-beta-lactamase-producing Pseudomonas aeruginosa: epidemiology, microbiology, and clinical outcomes. Antimicrob Agents Chemother 2006; 50:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14775/abstract/24\">",
"      Endimiani A, Luzzaro F, Pini B, et al. Pseudomonas aeruginosa bloodstream infections: risk factors and treatment outcome related to expression of the PER-1 extended-spectrum beta-lactamase. BMC Infect Dis 2006; 6:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14775/abstract/25\">",
"      Pe&ntilde;a C, Suarez C, Gozalo M, et al. Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections. Antimicrob Agents Chemother 2012; 56:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14775/abstract/26\">",
"      Aliaga L, Mediavilla JD, Llos&aacute; J, et al. Clinical significance of polymicrobial versus monomicrobial bacteremia involving Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis 2000; 19:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14775/abstract/27\">",
"      Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med 1985; 145:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14775/abstract/28\">",
"      Ibrahim EH, Sherman G, Ward S, et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14775/abstract/29\">",
"      Baltch AL, Hammer M, Smith RP, Sutphen N. Pseudomonas aeruginosa bacteremia: susceptibility of 100 blood culture isolates to seven antimicrobial agents and its clinical significance. J Lab Clin Med 1979; 94:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14775/abstract/30\">",
"      Hilf M, Yu VL, Sharp J, et al. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 1989; 87:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14775/abstract/31\">",
"      Todeschini G, Franchini M, Tecchio C, et al. Improved prognosis of Pseudomonas aeruginosa bacteremia in 127 consecutive neutropenic patients with hematologic malignancies. Int J Infect Dis 1998; 3:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14775/abstract/32\">",
"      Kuikka A, Valtonen VV. Factors associated with improved outcome of Pseudomonas aeruginosa bacteremia in a Finnish university hospital. Eur J Clin Microbiol Infect Dis 1998; 17:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14775/abstract/33\">",
"      Scheetz MH, Hoffman M, Bolon MK, et al. Morbidity associated with Pseudomonas aeruginosa bloodstream infections. Diagn Microbiol Infect Dis 2009; 64:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14775/abstract/34\">",
"      Jeddi R, Gh&eacute;dira H, Ben Amor R, et al. Risk factors of septic shock in patients with hematologic malignancies and Pseudomonas infections. Hematology 2011; 16:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14775/abstract/35\">",
"      Reyes MP, Palutke WA, Wylin RF. Pseudomonas endocarditis in the Detroit Medical Center. 1969-1972. Medicine (Baltimore) 1973; 52:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14775/abstract/36\">",
"      Wieland M, Lederman MM, Kline-King C, et al. Left-sided endocarditis due to Pseudomonas aeruginosa. A report of 10 cases and review of the literature. Medicine (Baltimore) 1986; 65:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14775/abstract/37\">",
"      Gou&euml;llo JP, Asfar P, Brenet O, et al. Nosocomial endocarditis in the intensive care unit: an analysis of 22 cases. Crit Care Med 2000; 28:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14775/abstract/38\">",
"      Komshian SV, Tablan OC, Palutke W, Reyes MP. Characteristics of left-sided endocarditis due to Pseudomonas aeruginosa in the Detroit Medical Center. Rev Infect Dis 1990; 12:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14775/abstract/39\">",
"      Reyes MP, Lerner AM. Current problems in the treatment of infective endocarditis due to Pseudomonas aeruginosa. Rev Infect Dis 1983; 5:314.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2136 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-9D3D6B0F7E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_27_14775=[""].join("\n");
var outline_f14_27_14775=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H296145128\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACTEREMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Septic shock",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Ecthyma gangrenosum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ENDOCARDITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H296144973\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H296145128\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H296145101\">",
"      Bacteremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H296145136\">",
"      Endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2136\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2136|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/43/27314\" title=\"picture 1\">",
"      Ecthyma gangrenosum",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=related_link\">",
"      Diagnostic approach to infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37464?source=related_link\">",
"      Epidemiology, pathogenesis, and microbiology of intravascular catheter infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5449?source=related_link\">",
"      Pathophysiology of sepsis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22297?source=related_link\">",
"      Surgery for native valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39528?source=related_link\">",
"      Treatment of Pseudomonas aeruginosa infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_27_14776="Spatial organization of intestinal microbiota in health and disease";
var content_f14_27_14776=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Spatial organization of intestinal microbiota in health and disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/27/14776/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/27/14776/contributors\">",
"     Alexander Swidsinski, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/27/14776/contributors\">",
"     Vera Loening-Baucke, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/27/14776/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/27/14776/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/27/14776/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/27/14776/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/27/14776/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The alimentary tract represents an interface between the external environment and the body. Within it exists a complex polymicrobial ecology that interacts with the internal and external environment and has an important influence on health and disease.",
"   </p>",
"   <p>",
"    The properties of isolated microorganisms do not explain how the polymicrobial community functions or why its organisms can grow under conditions that should be deadly to them [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14776/abstract/1\">",
"     1",
"    </a>",
"    ]. An understanding of how microorganisms interact with each other, their host, and the luminal contents is expanding rapidly.",
"   </p>",
"   <p>",
"    A major advance in understanding the function of the intestinal microbiota has been the development of techniques that permit a detailed assessment of the composition of the flora and its distribution throughout the alimentary tract. One of the methods to visualize single bacterial species within complex communities is called ribosomal RNA fluorescence in situ hybridization (FISH).",
"   </p>",
"   <p>",
"    Each bacterium possesses tens of thousands of ribosomes, each of which includes a copy of the bacterial RNA. Some of the regions of the ribosomal RNA are strain-specific, others are universal for groups, domains, or even kingdoms. Synthetically produced oligonucleotides that are complementary to sequences of interest can be labeled with fluorescent dye and added to samples containing bacteria. These oligonucleotides, called FISH probes, hybridize with RNA of bacterial ribosomes. Bacteria can be visualized with the microscope directly without additional enhancement because of the high number of ribosomes within each bacterium [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14776/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The names of the FISH probes described in this topic review are based on abbreviations of probeBase online resource for rRNA targeted oligonucleotide probes (",
"    <a class=\"external\" href=\"file://www.microbial-ecology.net/probebase/credits.asp\">",
"     www.microbial-ecology.net/probebase/credits.asp",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14776/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EVOLUTION'S ROLE IN THE DISTRIBUTION OF INTESTINAL MICROBIOTA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Animals have developed multiple mechanisms to control bacteria that enter the digestive tract, which can be broadly divided into those that suppress their growth (eg, salivary lysozyme, gastric acid, secretion of defensins) or those that separate them from the host by creating a physical barrier (eg, the mucus barrier). Polymicrobial communities such as exist in the intestine are much more resilient to these defenses than bacterial monocultures. They exhibit a coordinated response to environmental challenges, resist antibiotics, and can evade the host's immune response and are thus able to persist under extreme conditions.",
"   </p>",
"   <p>",
"    As a result, the control of bacterial growth by the host is never absolute and the intestine is never sterile. The occurrence, composition, and organization of intestinal microbiota in each gut segment depend upon whether suppression or separation dominates. In gut regions with active suppression of microbiota, the bacteria are occasional, of variable composition, and of low concentration. A complete separation of bacteria from the mucosa and low levels of suppression lead to the development of an intestinal reservoir in which bacteria can grow and reach high concentrations. Bacteria are indigenous to these intestinal regions.",
"   </p>",
"   <p>",
"    The balance of suppression and separation mechanisms depends upon the evolutionary impact of bacteria on promoting health or causing disease. As an example, plant feeding animals use microorganisms to digest cellulose, which would otherwise be indigestible. Thus, bacteria that digest cellulose are indigenous to the rumen of these animals. On the other hand, the nutrients resulting from bacterial degradation in ruminates are resorbed in the small intestine where bacteria would be clear competitors and are therefore suppressed. Thus, bacteria are occasional and present in only low concentrations in the small intestine.",
"   </p>",
"   <p>",
"    Similarly, bacteria in the colon are important for maintaining the health of colonic enterocytes and for digesting nutrients that could not be absorbed in the small bowel. As a result, bacteria exist in high concentrations in the colon (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Bacteria in the colon'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     BACTERIA IN THE UPPER GASTROINTESTINAL TRACT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mouth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microorganisms from the external world first contact the alimentary tract in the mouth. Bacteria can be found in high concentrations on food remnants, the dental surface and within or attached to desquamated epithelial cells, and suspended in oral secretions. There are also high concentrations of bacteria in saliva [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14776/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the high concentration of bacteria in the oral cavity, samples taken from the stratified epithelium of the mouth and saliva taken directly from the salivary duct are virtually sterile in healthy persons. This reflects defensive mechanisms working in concert to suppress bacterial adhesion and growth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Tonsils",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to the rest of the oral cavity, no constant pattern of colonization can be found on the surface of the tonsillar epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14776/abstract/5\">",
"     5",
"    </a>",
"    ]. Most of the epithelial surface of tonsils is free of bacteria even in tonsillectomy specimens obtained from individuals with chronic tonsillitis (",
"    <a class=\"graphic graphic_picture graphicRef55543 \" href=\"UTD.htm?14/24/14723\">",
"     picture 1",
"    </a>",
"    ). When bacteria were found, they were localized either to circumscribed regions of diffuse infiltration, within macrophages, superficial infiltrates, singular purulent fissures, or abscesses. The composition of bacteria within infectious tonsillar foci varies among individuals and often differs even between different regions of the same tonsil, indicating that bacteria are not indigenous to the tonsils but represent remnants of an incompletely cured purulent process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Stomach and duodenum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cultures of fluid from the stomach or duodenum of healthy volunteers contain bacterial concentrations of 10(3) to",
"    <span class=\"nowrap\">",
"     10(4)/mL,",
"    </span>",
"    depending in part upon the composition of digested food. Fluorescence in situ hybridization demonstrates that bacteria in the stomach and duodenum are localized strictly within the intestinal lumen and separated from the mucosa by a mucus layer. Their composition is variable, reflecting the heterogeneous composition of the ingested flora. In healthy individuals, the mucosa and the mucus layer of the stomach and duodenum are free of bacteria. In patients with Helicobacter pylori infection, the mucosal surface of the stomach is covered with a bacterial biofilm in which Helicobacter pylori is predominant [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14776/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pancreatic tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;The microflora of the normal pancreatic duct has not been extensively studied since samples available from healthy individuals are not readily available. FISH analysis of pancreatic duct biopsies obtained during ERCP from patients with benign or malignant obstruction of the pancreatic duct have demonstrated islands of bacterial adhesion in about 70 percent of the biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14776/abstract/7\">",
"     7",
"    </a>",
"    ]. The anatomically normal pancreatic duct epithelium is generally sterile. Thus, bacterial islands appear to be located in regions of disturbed duct anatomy. Bacterial species in the pancreatic duct are diverse and highly variable among individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Biliary tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsies of healthy bile ducts are not readily available and thus the microflora of the biliary epithelium in health has not been extensively evaluated. Gallbladder resection specimens obtained from patients who did not receive preoperative antibiotics are free of bacteria, indicating that the bile duct epithelium is normally not colonized.",
"   </p>",
"   <p>",
"    The situation is different in the presence of foreign bodies such as biliary stents (",
"    <a class=\"graphic graphic_picture graphicRef54167 \" href=\"UTD.htm?22/21/22867\">",
"     picture 2",
"    </a>",
"    ). The colonization of the biliary stents by polymicrobial biofilm can be documented within a week after implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14776/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Both aerobic and anaerobic bacteria, which are commonly found in the intestine, can be identified. The microbial colonization starts with the distal end of the biliary stent and advances proximally. Bacteria are located mainly on the inner surface of plastic stents. By contrast, the surface of biliary stents facing normal epithelium is not colonized, indicating that the healthy epithelial layer efficiently resists microbial colonization [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14776/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rapid development of biofilms at the inner surface of the biliary stents indicates that the biliary and pancreatic secretions alone are unable to prevent the development of bacterial biofilms on foreign bodies. Interestingly, the bacterial biofilm disappears as soon as the stent is occluded by sludge, suggesting that organic substances in sludge help prevent bacterial growth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Gallstones",
"    </span>",
"    &nbsp;&mdash;&nbsp;A similar trend of the bacterial biofilm vanishing after local deposition of organic substances can be observed in gallstones. Because gallstones are essentially foreign bodies, they should be permanently colonized. Bacteria can indeed be found in loose brown pigment stones and sludge, which are an initial stage in the formation of gallstones.",
"   </p>",
"   <p>",
"    The natural history of the gallstone is a progression from brown to composite and then to cholesterol gallstones. The cholesterol stones can reach considerable sizes and persist in the human body over many decades. Nevertheless, cholesterol gallstones obtained after cholecystectomy are mostly sterile. This suggests that sedimentation of cholesterol and sludge within the bacterial biofilm is an integral part of some kind of protective mechanism against otherwise extremely recalcitrant infections [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14776/abstract/7\">",
"     7",
"    </a>",
"    ]. The body's sedimentary mechanism as a defense appears extremely efficient in suppressing bacterial biofilms on foreign bodies when compared to the complete ineffectiveness of presently available antibiotics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Small intestine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epithelial surface of the small intestine in a healthy human is not colonized. Occasional groups of bacteria can be found in low concentrations of 10(5) or less within the lumen. Bacteria do not form conglomerates and spatial structures and the luminal contents are separated from the mucosa by a mucus layer.",
"   </p>",
"   <p>",
"    The situation is similar in mice but not in rats. In most groups of wild-type rats, segmented filamentous bacteria (SFB) can be observed tightly attached to the epithelial surface and located between villi throughout the small intestine. The SFB adherence in rats is not accompanied by an increase in concentrations of other bacterial groups or leukocytes. It is difficult to say whether segmented filamentous bacteria are pathogens such as Helicobacter species, saprophytic or symbiotic bacteria with an unknown role, because of the high prevalence of adherent SFB in the small intestines of wild-type rats.",
"   </p>",
"   <p>",
"    In humans, the adherence of segmented filamentous bacteria has not been observed either in health or disease. Pathologic conditions with altered microbiota in the small intestine include acute and chronic infections, bacterial overgrowth, and inflammatory bowel disease (IBD). Common to all of these conditions are a disruption of the mucus barrier, loss of bacterial separation between mucosa and lumen, bacterial adherence, invasion, and translocation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14776/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Disruption of the mucus barrier'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     BACTERIA IN THE COLON",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     The role of microbiota in colonic function",
"    </span>",
"    &nbsp;&mdash;&nbsp;The large intestine is a bioreactor in which the host uses bacteria to degrade indigestible leftovers. Bacteria produce valuable substances such as vitamins and short fatty acids by degrading waste products.",
"   </p>",
"   <p>",
"    In humans, resorption in the large intestine is restricted mostly to water and electrolytes. Bacteria in the human colon are mainly responsible for the reduction of the fecal mass. Which bacterial species are responsible for these processes are not well known. However, a reasonable assumption is that the numerically predominant bacteria are indispensable for the biochemical processes that occur in the colon. Eubacterium rectale (Roseburia spp), Faecalibacterium prausnitzii, and Bacteroides groups comprise each 10 to 30 percent and cumulative 70 percent of the total microbiota in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14776/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. All other bacterial groups are present only in subgroups of individuals or in parts of the colon.",
"   </p>",
"   <p>",
"    Although the fecal flora is one of the most well characterized microbiota, many of the bacterial species inhabiting the large intestine are unknown. Strict anaerobic species predominate, although the diversity of bacteria is high and consists of about 3000 to 5000 species [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14776/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the colon, bacteria reach concentrations of up to the",
"    <span class=\"nowrap\">",
"     10(11)/mL",
"    </span>",
"    and compose up to 90 percent of the fecal mass. Such high bacterial concentrations can be achieved only under active facilitation of bacterial growth. Bacterial growth is facilitated by peristalsis (which extensively mixes bacteria with fibers), and maintenance of optimal viscosity and temperature. However, the most astonishing feature promoting colonic bacterial growth is the virtual lack of mechanisms to suppress it.",
"   </p>",
"   <p>",
"    It was initially believed that the immune system was tightly regulated to respond to pathogenic intestinal bacteria while tolerating commensal bacterial. However, it is increasingly recognized that bacterial residents of the large bowel cannot be easily divided as being pathogenic or nonpathogenic. Many of indigenous bacteria are known pathogens. As examples, Escherichia coli cause sepsis, Bacteroides cause abscesses, Enterococci cause endocarditis, and Clostridium histolyticum causes gas gangrene. These bacterial groups are considered normal inhabitants of the human colon because they can be found in every healthy person. FISH analysis of the mucosal flora has clearly demonstrated that the host does not tolerate the indigenous microbiota, but separates them from contact with the mucosa.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Mucus barrier",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonic and ileal biopsies from healthy persons are covered with mucus, which is free of bacteria. The separation of fecal bacteria from the mucosa by mucus can be seen in sections of normal appendices, which were resected for suspected acute appendicitis and found to be normal (",
"    <a class=\"graphic graphic_picture graphicRef81208 \" href=\"UTD.htm?8/14/8421\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A similar separation of colonic bacteria from the mucosa can be observed in the distal colon of rodents. In contrast to humans, bacteria in the proximal colon of rats and mice directly contact the colonic wall and enter crypts in high concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14776/abstract/13\">",
"     13",
"    </a>",
"    ]. However, contact of bacteria with the mucosa in the proximal colon of mice is selective. Long curly rods of Eubacterium rectale contact the mucosa and enter crypts in large numbers, while short coccoid rods of Bacteroides are separated from the colonic wall. The differences in arrangement of bacterial groups are especially obvious in multicolor FISH simultaneously visualizing different bacterial species.",
"   </p>",
"   <p>",
"    Analysis of bacterial groups from the proximal colon of mice reveals that only long rods with a curly form contact the mucosa (Eubacterium rectale, Bifidobacteriaceae Lactobacillius). Short rods and coccoid bacteria such as Bacteroides, Enterobacteriaceae, Clostridium difficile, Veillonella, and other groups are separated from the mucosa. The difference in the spatial distribution of differently shaped bacteria in the proximal colon of mice indicates that the mucus layer in the proximal colon of rodents is also present. However, because of a lower viscosity, it is penetrable for long corkscrew formed bacteria but not for short coccoid rods.",
"   </p>",
"   <p>",
"    The shape of bacteria is important for their movement. Short rods are equipped with multiple pili that permit movements in a watery environment but not in slime. Short rods have flagella, which act like propellers to move them through slime. Long curly rods use complex body movements to screw through gels of high viscosity, but are immobile in water. Studies on velocity of differently shaped bacteria in simulated mucus with variable viscosity indicate that the coccoid Bacteroides bacteria have the highest velocity at viscosity corresponding to 0.2 percent agarose and are immobilized at 0.4 percent agarose, while the long curly rods of the Eubacterium rectale group have the highest velocity at viscosity of 0.5 percent agarose. All bacterial movements stop at viscosity of 0.7 percent agarose in the simulated mucus [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14776/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The distribution of long curly bacteria or short coccoid rods within mucus can be used to mark the areas of changing viscosity. In healthy humans, the separation of bacteria from the mucosa is equal in the proximal and distal colon and bacteria are never found in crypts. In healthy rodents, the viscosity of the mucus in the proximal colon is markedly lower than in the distal colon, allowing bacteria with a long curly rod shape to reach and contact the mucosa.",
"   </p>",
"   <p>",
"    The reason for differences in mucus layer viscosity of the proximal colon in humans is unclear. The adherence of selected bacterial groups may have some unknown evolutionary advantages. The overall surface of a mouse colon is much smaller than that of a human. The reduced viscosity in the proximal colon creates compartments between crypts that contain bacterial stocks needed for re-starting the colonic bioreactor.",
"   </p>",
"   <p>",
"    The mucus layer is continuously renewed. Changes in viscosity of the mucus layer are controlled by two opposite processes. Mucus is solidified near the mucosa where active resorption of water takes place while it is diluted (and therefore becomes less viscous) near the lumen because of contact with water contained in the fecal stream. The viscosity of the mucus secreted by goblet cells is significantly lower than the viscosity of the dehydrated mucus film, which is attached to the columnar epithelium. The secreted mucus cannot combine with the dehydrated mucus because of differences in consistency. Instead, it pushes the dehydrated mucus toward the lumen and spreads below it. This process protects freshly secreted mucus from bacterial penetration until it is in turn solidified by water resorption and can serve as impenetrable cover. This process is visible histologically as onion-like stratification of the mucus layer, which can be seen in alcian stain, or even better with FISH (",
"    <a class=\"graphic graphic_picture graphicRef52286 \" href=\"UTD.htm?24/0/24579\">",
"     picture 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Biostructure of fecal microbiota",
"    </span>",
"    &nbsp;&mdash;&nbsp;The structure of fecal microbiota within the intact intestine cannot be directly studied in humans since intestinal specimens filled with feces cannot be readily obtained from healthy persons. However, the spatial organization of fecal microbiota can be evaluated from stool specimens in which the outer layer represents the luminal surface of the intestinal mucus layer. The spatial structure of fecal microbiota can be investigated on sections of punched out fecal cylinders, which are then fixated and embedded in paraffin [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14776/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].The technique is analogous to the examination of stratified geologic structures by studying core samples.",
"   </p>",
"   <p>",
"    In healthy humans, the surface of formed stools is covered with a mucus layer similar to the mucus covering the mucosal surface of biopsies. Fecal microbiota in healthy humans can be divided into habitual bacterial groups present in all subjects and occasional bacteria, which are present only in subgroups, either diffusely or locally.",
"   </p>",
"   <p>",
"    The term \"habitual\" as used in this context is not synonymous with \"commensal\". Commensal bacteria include certain bacterial groups such as Bifidobacteriaceae, Enterobacteriaceae, Clostridia, Lactobacilli, and Enterococci, which are often present, but not obligatory for the healthy human intestine, and whose presence, absence, or alteration in number do not reflect whether the colon is healthy or diseased.",
"   </p>",
"   <p>",
"    Studies evaluating 86 different bacterial groups have demonstrated that Eubacterium rectale (Roseburia spp.), Bacteroides, and Faecalibacterium prausnitzii groups are habitual and each comprise 20 to 50 percent of the fecal flora and together at least 70 percent of all bacteria present in feces [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14776/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. All other bacterial groups occur only in a subset of patients.",
"   </p>",
"   <p>",
"    With regard to the mucus layer, bacteria can be divided in fecomucous (bacteria that tend to live within feces), mucophob (bacteria that tend to avoid mucus), and mucotroph (bacteria that tend to live within mucus). All habitual bacteria are fecomucous; their highest concentrations are within feces, although they also enter mucus. Their concentrations diminish with increasing distance from the fecal surface. The mucophob bacteria (such as the Bifidobacteriaceae group) avoid mucus. Mucotroph bacteria (such as Enterobacteriaceae and Verucomicriaceae) are located on the border between feces and mucus.",
"   </p>",
"   <p>",
"    The biostructure and composition of bacterial groups varies among individuals. Within individuals, the fecal biostructure and composition are generally stable from day to day but change substantially when studies have been performed repeatedly for more than six months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DISRUPTION OF THE MUCUS BARRIER",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prominent feature of intestinal inflammation is disruption of the mucus barrier (",
"    <a class=\"graphic graphic_picture graphicRef64110 \" href=\"UTD.htm?30/42/31394\">",
"     picture 5",
"    </a>",
"    ). Once this occurs, bacteria migrate toward the mucosa where they build dense layers adherent to epithelial cells resulting in cytopathologic effects. Bacteria are generally located at the bottom of the crypts [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14776/abstract/9\">",
"     9",
"    </a>",
"    ]. They can also be seen in regions that have been mechanically damaged (such as biopsy sites); thus, reports of submucosal bacteria should be interpreted cautiously unless they demonstrate the intact mucosal surface surrounding the presumed infiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14776/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite massive adhesion, the epithelial barrier generally protects against deeper bacterial invasion. It is uncommon to find bacteria within epithelial cells or within submucosal regions even in patients with severe intestinal inflammation.",
"   </p>",
"   <p>",
"    Interestingly, the highest concentrations of mucosal bacteria are found not in the inflamed regions of the intestine but rather in relatively non-inflamed regions, suggesting that disruption of the mucus barrier occurs before the onset of intestinal inflammation. In inflamed regions, the bacterial concentrations are reduced, while leukocytes appear in the mucus in large numbers often forming arrays in the outer regions of the mucus. Leukocytes within mucus are absent in biopsies from healthy persons. Despite the high concentrations of leukocytes in mucus, the bacteria eventually reach the intestinal wall leading to development of ulcers, fissures, and crypt abscesses.",
"   </p>",
"   <p>",
"    Disruption of the mucus barrier and bacterial adherence to the mucosa is not specific to IBD. Bacterial concentrations of 10(9)",
"    <span class=\"nowrap\">",
"     bacteria/mL",
"    </span>",
"    or higher can be found within mucus in nearly all patients with IBD but also in patients with celiac disease, and nearly one-half of patients with a variety of conditions including acute diarrhea, diverticulosis, colon cancer or polyps and about 40 percent of patients with irritable bowel syndrome (IBS) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14776/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 90 percent of bacteria found in mucus of patients with these diseases are represented by only three groups: Bacteroides, Eubacterium rectale, and Faecalibacterium prausnitzii (",
"    <a class=\"graphic graphic_picture graphicRef64110 \" href=\"UTD.htm?30/42/31394\">",
"     picture 5",
"    </a>",
"    ). The mean density of the mucosal bacteria is significantly lower in non-IBD disease controls and the composition of the biofilm differs. Bacteria of the Bacteroides fragilis group are responsible for &gt;50 percent of the biofilm mass in IBD. By contrast, bacteria that positively hybridize with the Erec (Eubacterium rectale) and Fprau (Faecalibacterium prausnitzii) probes account for &gt;50 percent of the biofilm in patients with irritable bowel syndrome, but account for &lt;30 percent of the biofilm in IBD.",
"   </p>",
"   <p>",
"    Despite these differences, there is variability among individuals making differentiation among Crohn's disease, ulcerative colitis, irritable bowel syndrome, diverticulosis, or colonic cancer based solely upon the FISH analysis of the mucosal flora at present impossible. Even Faecalibacterium prausnitzii, which is completely depleted in the feces of patients with Crohn's disease, cannot be used as a reliable marker for diagnosis of Crohn's disease. It can be detected in the mucus of colonoscopic biopsies from more than 50 percent of patients with Crohn's disease, but it is absent in most of the biopsies from healthy persons.",
"   </p>",
"   <p>",
"    The situation is different in patients with self-limiting colitis or specific infections such as Serpulina, Fusobacterium necrophorum (nucleatum), or Whipple's disease. In such patients, disruption of the mucus barrier is associated with an increase in bacterial groups other than Fprau+Erec+Bac so that they constitute 10 to 70 percent of bacterial mass.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Unrecognized pathogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several theories have been proposed to explain the increasing incidence of autoimmune and allergic conditions since the twentieth century. One of these, the hygiene hypothesis, argues that improved hygiene and a lack of exposure to microorganisms of various types in early childhood have led to a lack of immunologic tolerance to ubiquitous environmental antigens.",
"   </p>",
"   <p>",
"    Multiple studies have provided epidemiologic evidence in support of a link between higher hygienic standards and increased incidence of IBD. However, no studies have specifically examined the hygiene hypothesis as it pertains to the composition of the intestinal flora. There are also no data that point to major differences in the number or diversity of the colonic flora in individuals living in urban versus rural areas.",
"   </p>",
"   <p>",
"    An alternative hypothesis related to microbiological exposures may be that the increase in allergies and atopic conditions is not directly due to lack of exposure to certain microorganisms but rather due to exposure to previously unrecognized pathogens. The ubiquitous availability of produce from around the world and the mobility of modern society have led to the profound and rapid exchange of bacteria worldwide. As a result, exposure to facultative pathogens has likely increased. Concurrently, there may have been a shift from the more clinically apparent pathogens (such as Cholera, Salmonella, Shigella, and Yersinia) to those whose deleterious effects are more difficult to recognize. The clinical significance of Helicobacter pylori, for example, was not appreciated until the late twentieth century.",
"   </p>",
"   <p>",
"    The list of enteric bacteria that are potentially capable of causing disease is growing. Examples include Serpulina, Fusobacteria, adhesive Enterobacteriaceae, and Gardnerella, although their clinical importance is still being studied. Common to some of these organisms is the ability to compromise the mucus barrier and provide niches for growth of other enteric bacteria that normally do not have access to the mucosa (",
"    <a class=\"graphic graphic_picture graphicRef75549 \" href=\"UTD.htm?4/53/4947\">",
"     picture 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14776/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Substances that reduce the viscosity of the mucus barrier",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another potential explanation for the hygiene hypothesis is that the decrease in microbiologic exposures is not the root of the problem but rather correlates with the introduction of ingested detergents that disrupt the intestinal mucus barrier. We know astonishingly little about the effects of detergents on the intestinal mucosa and the mucus barrier, despite their longtime use. However, in vitro and in vivo evidence suggests substances that reduce the viscosity of mucus thereby potentially contribute to bacterial proliferation on the intestinal mucosa.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Detergents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The addition of detergents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    sodium sulfate (DSS) to an in vitro model of stimulated mucus enables migration of bacteria through gels with a viscosity corresponding to agarose concentrations of 0.9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14776/abstract/14\">",
"     14",
"    </a>",
"    ]. Bacteroides migration could be seen in concentrations of up to 0.6 percent and migration of the Eubacterium rectale group up to 0.9 percent. Without detergents, Bacteroides is immobilized at viscosity corresponding to agarose concentration of 0.4 percent and the migration of all bacterial groups stops at viscosity corresponding to an agarose concentrations of 0.7 percent.",
"   </p>",
"   <p>",
"    Although the effects of detergents on the mucosal barrier in humans are unknown, in the mouse model, the addition of DSS to food induces acute colitis, which becomes chronic after repeated exposure to DSS [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14776/abstract/18\">",
"     18",
"    </a>",
"    ]. The DSS induced inflammation in mice is restricted to the large intestine, where bacterial concentrations are high, and bypasses the small intestine, where bacterial concentrations are low. Antibiotics relieve the DSS induced inflammation.",
"   </p>",
"   <p>",
"    DSS is absent in the human food supply. However, traces of dish washing detergents are ingested with our food. The \"cleaning\" effects of ingested home soaps on colonic mucus have never been investigated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Emulsifiers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emulsifiers are another group of substances that could potentially influence the mucus barrier and have been used increasingly by the food industry since the beginning of the twentieth century. Data on IL-10 gene-deficient mice support the potentially detrimental role of emulsifiers, such as 2 percent carboxymethyl cellulose (CMC) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14776/abstract/19\">",
"     19",
"    </a>",
"    ]. High bacterial concentrations were found within crypts of Lieberkuhn in the ileum of all CMC treated IL-10 knock-out mice. The finding grossly resembled those found in the ileum of patients with Crohn's disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Other causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other substances can potentially perturb the mucus barrier including bile salts, glutens, cigarette smoking, stress, and defensins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     BIOSTRUCTURE OF FECAL MICROBIOTA IN HEALTH AND INFLAMMATORY BOWEL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The colon is a highly efficient bioreactor that is vulnerable to malfunction in the setting of inflammation or other GI disorders. Most studies of the intestinal microflora have been based on homogenized stools samples, making it impossible to evaluate special perturbations in the organization of the colonic bioreactor. Contemporary techniques described above are revealing new insights into how the bioreactor is structured and responds to disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14776/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Functionally, the colonic bioreactor can be divided into three zones:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A transparent outer mucus layer, which is constantly dehydrated by the columnar epithelium, and is therefore highly viscous, impenetrable to bacteria, and separates the colonic bioreactor from the mucosa.",
"     </li>",
"     <li>",
"      A central&nbsp;fermenting zone in which bacteria and fibers are stirred and fermented.",
"     </li>",
"     <li>",
"      A transitional resting zone between the mucus layer and central zone in which mucus is increasingly diluted by luminal fluids and can be penetrated by bacteria. The softened mucus stays attached to the colonic wall for a prolonged time. Bacteria enter these soft portions of the mucus in concentrations that are inversely proportionate to the growing viscosity gradient and, as a result, they become increasingly immobilized (",
"      <a class=\"graphic graphic_picture graphicRef79161 \" href=\"UTD.htm?4/60/5060\">",
"       picture 7",
"      </a>",
"      ). Trapped within the resting zone, bacteria are protected against purging events and are therefore available to repopulate the bioreactor after occasional cleanouts such as during periods of fasting, diarrhea, or even antibiotic treatment. Thus, bacteria within the resting zone represent germinal stocks of the colonic bioreactor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The firm mucus can be seen easily on alcian stain. In healthy subjects, both the resting (germinal) zone and the luminal (fermenting) area cannot be distinguished from each other. When the colonic bioreactor functions properly, the composition and density of bacteria found in these regions are similar. By contrast, in various diseases, the microbial changes in these compartments are different and disease specific.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Nonspecific changes of the colonic microbial biostructure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several nonspecific changes to the colonic microbial biostructure occur in a variety of disease states:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diarrhea of any cause is associated with increased thickness of the mucus layer and growing incorporation of the unstructured mucus within the fecal mass (",
"      <a class=\"graphic graphic_picture graphicRef55638 \" href=\"UTD.htm?13/47/14071\">",
"       picture 8",
"      </a>",
"      ). Patients with ulcerative colitis are an exception; in such patients the mucus layer is depleted.",
"     </li>",
"     <li>",
"      A common feature of several intestinal disorders is a suppression of bacterial growth and metabolism at the center of the bioreactor. However, as a general rule, the suppression is most apparent with habitual bacterial groups. Their concentrations in healthy persons are especially high and the distribution throughout the fecal cylinder is normally homogenous. Initially, only the fluorescence signals fade. This fading is apparent in the phenomenon of hybridization silence, because the number of bacteria stays constant from suppressed to unsuppressed regions and only hybridization signals of bacteria change (relative hybridization silence). With progression, however, the hybridization signals of single bacterial groups may disappear completely (absolute hybridization silence) and it is impossible to discriminate between suppression and physical elimination of bacteria [",
"      <a class=\"abstract\" href=\"UTD.htm?14/27/14776/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The epicenter of suppression is located in the center of feces and, with an exception in Crohn's disease, does not involve the superficial \"germinal\" zone of the fecal cylinder, where the fluorescence of bacteria and bacterial numbers remain high (",
"    <a class=\"graphic graphic_picture graphicRef57920 \" href=\"UTD.htm?11/39/11891\">",
"     picture 9",
"    </a>",
"    ). The production of the suppressive substance must take place in the small intestine or at least upstream from the colon [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14776/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Changes of the colonic microbial biostructure in IBD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Changes involving the germinal bacterial zone are characteristic for active inflammatory bowel disease and absent in most other disease control groups. The most prominent feature of ulcerative colitis is a replacement of the mucus layer by leukocytes. The leukocytes are located in the germinal zone, which they progressively destroy (",
"    <a class=\"graphic graphic_picture graphicRef58004 \" href=\"UTD.htm?28/37/29268\">",
"     picture 10",
"    </a>",
"    ). Active Crohn's disease is characterized by complete depletion of Faecalibacterium prausnitzii from the central and germinal zones of feces. The reproducible detection of these two features in three consecutive fecal cylinders taken in two-weekly intervals allows the diagnosis of active Crohn's disease and ulcerative colitis with a 79 and 80 percent sensitivity and 98 and 100 percent specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14776/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The surface of the intestinal tract in healthy individuals is free of bacteria in all bowel segments. Adherence of bacteria to epithelial cells is thus a sign of infection. By contrast, the intestinal lumen is never sterile.",
"     </li>",
"     <li>",
"      The occurrence, composition, and organization of intestinal microbiota in each gut segment depend upon whether suppression (mechanisms that suppress bacterial growth) or separation (mechanisms that create a physical barrier from the host such as the mucus layer) dominates. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Evolution's role in the distribution of intestinal microbiota'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It was initially believed that the immune system was tightly regulated to respond to pathogenic intestinal bacteria while tolerating commensal bacterial. However, it is increasingly recognized that bacterial residents of the large bowel cannot be easily divided as being pathogenic or nonpathogenic. Many indigenous bacteria are known pathogens. As examples, Escherichia coli cause sepsis, Bacteroides cause abscesses, Enterococci cause endocarditis, and Clostridium histolyticum causes gas gangrene. The control of pathogens and the regulation of the colonic bioreactor require proper function of the intestinal mucus layer. Before bacteria can adhere and invade the mucosa, they must first traverse the mucus layer. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Disruption of the mucus barrier'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The structure and composition of intestinal bacteria can be markedly affected in the presence of a variety of diseases states. For example, inflammatory bowel disease is a polymicrobial infection that is characterized by a sustained broken mucus barrier, subsequent bacterial migration towards the mucosa and proliferation of a complex bacterial biofilm on the epithelial surface with resulting invasive and cytopathologic effects. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Biostructure of fecal microbiota in health and inflammatory bowel disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The composition and structure of fecal microbiota changes as a consequence of the inflammatory response. Active Crohn's disease and ulcerative colitis can be distinguished from each other and other disease controls based upon the biostructure of fecal cylinders. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Biostructure of fecal microbiota'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14776/abstract/1\">",
"      Kuramitsu HK, He X, Lux R, et al. Interspecies interactions within oral microbial communities. Microbiol Mol Biol Rev 2007; 71:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14776/abstract/2\">",
"      Amann RI, Ludwig W, Schleifer KH. Phylogenetic identification and in situ detection of individual microbial cells without cultivation. Microbiol Rev 1995; 59:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14776/abstract/3\">",
"      Amann R, Fuchs BM. Single-cell identification in microbial communities by improved fluorescence in situ hybridization techniques. Nat Rev Microbiol 2008; 6:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14776/abstract/4\">",
"      Loy A, Maixner F, Wagner M, Horn M. probeBase--an online resource for rRNA-targeted oligonucleotide probes: new features 2007. Nucleic Acids Res 2007; 35:D800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14776/abstract/5\">",
"      Swidsinski A, G&ouml;ktas O, Bessler C, et al. Spatial organisation of microbiota in quiescent adenoiditis and tonsillitis. J Clin Pathol 2007; 60:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14776/abstract/6\">",
"      Kandulski A, Selgrad M, Malfertheiner P. Helicobacter pylori infection: a clinical overview. Dig Liver Dis 2008; 40:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14776/abstract/7\">",
"      Swidsinski A, Schlien P, Pernthaler A, et al. Bacterial biofilm within diseased pancreatic and biliary tracts. Gut 2005; 54:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14776/abstract/8\">",
"      Scheithauer BK, Wos-Oxley ML, Ferslev B, et al. Characterization of the complex bacterial communities colonizing biliary stents reveals a host-dependent diversity. ISME J 2009; 3:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14776/abstract/9\">",
"      Swidsinski A, Weber J, Loening-Baucke V, et al. Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol 2005; 43:3380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14776/abstract/10\">",
"      Franks AH, Harmsen HJ, Raangs GC, et al. Variations of bacterial populations in human feces measured by fluorescent in situ hybridization with group-specific 16S rRNA-targeted oligonucleotide probes. Appl Environ Microbiol 1998; 64:3336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14776/abstract/11\">",
"      Harmsen HJ, Raangs GC, He T, et al. Extensive set of 16S rRNA-based probes for detection of bacteria in human feces. Appl Environ Microbiol 2002; 68:2982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14776/abstract/12\">",
"      Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol 2008; 6:e280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14776/abstract/13\">",
"      Swidsinski A, Loening-Baucke V, Lochs H, Hale LP. Spatial organization of bacterial flora in normal and inflamed intestine: a fluorescence in situ hybridization study in mice. World J Gastroenterol 2005; 11:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14776/abstract/14\">",
"      Swidsinski A, Sydora BC, Doerffel Y, et al. Viscosity gradient within the mucus layer determines the mucosal barrier function and the spatial organization of the intestinal microbiota. Inflamm Bowel Dis 2007; 13:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14776/abstract/15\">",
"      Swidsinski A, Loening-Baucke V, Verstraelen H, et al. Biostructure of fecal microbiota in healthy subjects and patients with chronic idiopathic diarrhea. Gastroenterology 2008; 135:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14776/abstract/16\">",
"      Swidsinski A, Loening-Baucke V, Vaneechoutte M, Doerffel Y. Active Crohn's disease and ulcerative colitis can be specifically diagnosed and monitored based on the biostructure of the fecal flora. Inflamm Bowel Dis 2008; 14:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14776/abstract/17\">",
"      Swidsinski A, Mendling W, Loening-Baucke V, et al. Adherent biofilms in bacterial vaginosis. Obstet Gynecol 2005; 106:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14776/abstract/18\">",
"      Okayasu I, Hatakeyama S, Yamada M, et al. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990; 98:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14776/abstract/19\">",
"      Swidsinski A, Ung V, Sydora BC, et al. Bacterial overgrowth and inflammation of small intestine after carboxymethylcellulose ingestion in genetically susceptible mice. Inflamm Bowel Dis 2009; 15:359.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2556 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-199.231.185.123-EFBF5593C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_27_14776=[""].join("\n");
var outline_f14_27_14776=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EVOLUTION'S ROLE IN THE DISTRIBUTION OF INTESTINAL MICROBIOTA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BACTERIA IN THE UPPER GASTROINTESTINAL TRACT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mouth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Tonsils",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Stomach and duodenum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pancreatic tract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Biliary tract",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Gallstones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Small intestine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      BACTERIA IN THE COLON",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      The role of microbiota in colonic function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Mucus barrier",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Biostructure of fecal microbiota",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DISRUPTION OF THE MUCUS BARRIER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Unrecognized pathogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Substances that reduce the viscosity of the mucus barrier",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Detergents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Emulsifiers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Other causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      BIOSTRUCTURE OF FECAL MICROBIOTA IN HEALTH AND INFLAMMATORY BOWEL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Nonspecific changes of the colonic microbial biostructure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Changes of the colonic microbial biostructure in IBD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2556\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2556|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/24/14723\" title=\"picture 1\">",
"      Tonsillar epith bacteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/21/22867\" title=\"picture 2\">",
"      Bacterial colonization of biliary stents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/14/8421\" title=\"picture 3\">",
"      DAPI transverse appendix",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/0/24579\" title=\"picture 4\">",
"      Distal colon wildtype mouse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/42/31394\" title=\"picture 5\">",
"      Inflammatory bowel disease colonic mucosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/53/4947\" title=\"picture 6\">",
"      Mucus barrier disruption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/60/5060\" title=\"picture 7\">",
"      Bacteria in resting zone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/47/14071\" title=\"picture 8\">",
"      Mucus layer IBS diarrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/39/11891\" title=\"picture 9\">",
"      Hybridization silence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/37/29268\" title=\"picture 10\">",
"      Fecal cylinder DAPI stain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_27_14777="Meta-analysis subgroup stratification I";
var content_f14_27_14777=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F70567&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F70567&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 644px\">",
"   <div class=\"ttl\">",
"    Meta-analysis subgroup stratification",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 624px; height: 509px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     THIS GRAPHIC IS CONTINUED IN THE FIGURE \"META-ANALYSIS SUBGROUP STRATIFICATION II\".",
"    </strong>",
"    <br>",
"     Size of the data markers indicates weight of the study.",
"     <div class=\"footnotes\">",
"      CI: confidence interval; VASSCSG: Veterans Administration Systemic Sepsis Cooperative Study Group.",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: Annane D, Bellissant E, Bollaert P, et al. Corticosteroids in the Treatment of Severe Sepsis and Septic Shock in Adults. JAMA 2009; 301:2362. Copyright &copy; 2009 American Medical Association. All rights reserved.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_27_14777=[""].join("\n");
var outline_f14_27_14777=null;
var title_f14_27_14778="Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction";
var content_f14_27_14778=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/27/14778/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/27/14778/contributors\">",
"     C Michael Gibson, MS, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/27/14778/contributors\">",
"     Thomas Levin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/27/14778/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/27/14778/contributors\">",
"     Christopher P Cannon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/27/14778/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/27/14778/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/27/14778/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plaque rupture and thrombus formation play a major role in the genesis of acute coronary occlusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=see_link\">",
"     \"The role of the vulnerable plaque in acute coronary syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The introduction of fibrinolytic (thrombolytic) therapy was a major advance in the treatment of acute ST elevation (Q wave) myocardial infarction (STEMI). Primary percutaneous coronary intervention (PCI) is now preferred for most patients if it can be performed by an experienced operator with less than a two hour delay from presentation to the emergency department. Due in part to limited availability of primary PCI, fibrinolytic therapy remains an important therapeutic modality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/46/16106?source=see_link\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In comparison, fibrinolytic therapy has largely not been effective in patients with a non-ST elevation MI (NSTEMI). Coronary arteriography, performed in the acute period following NSTEMI, demonstrates that the infarct-related artery is not occluded in 60 to 85 percent of cases. Since microvascular perfusion is often reduced in patients with NSTEMI, the ongoing mechanism of ischemia is more likely to be embolization than epicardial vessel occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22421?source=see_link\">",
"     \"Fibrinolytic (thrombolytic) agents in unstable angina and acute non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Currently used fibrinolytic drugs are intravenously infused plasminogen activators that activate the blood fibrinolytic system. These agents have a high specificity for their substrate plasminogen, hydrolyzing a peptide bond to yield the active enzyme plasmin. Free plasmin is rapidly neutralized by the serine proteinase inhibitor alpha-antiplasmin, whereas fibrin-bound plasmin is protected from rapid inhibition, thereby promoting clot lysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/40/28297?source=see_link\">",
"     \"Vascular endothelial function and fundamental mechanisms of fibrinolysis (thrombolysis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The characteristics of the different fibrinolytic agents (",
"    <a class=\"graphic graphic_table graphicRef56744 \" href=\"UTD.htm?25/33/26140\">",
"     table 1",
"    </a>",
"    ) and their efficacy in clinical trials of patients with STEMI will be reviewed here. The indications, contraindications, and adverse effects of these drugs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STREPTOKINASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Streptokinase is a single chain polypeptide derived from beta-hemolytic streptococcus cultures. It binds to plasminogen, forming a complex that becomes an active enzyme that cleaves peptide bonds on other plasminogen molecules, leading to plasmin activation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. High doses are necessary to neutralize the plasma levels of antistreptococcal antibodies.",
"   </p>",
"   <p>",
"    For acute MI, streptokinase is administered in a dose of 1.5 million units over 60 minutes. All patients receiving streptokinase therapy for acute myocardial infarction should also receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (325",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"    Although the routine use of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is supported for the fibrin-specific agents, the requirement for intravenous or subcutaneous heparin or of low molecular weight heparin with streptokinase is less clear. However, the AMI-SK trial suggested that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    might be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5018?source=see_link\">",
"     \"Anticoagulant therapy in acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse effects include allergic reactions, hypotension, and, as with all thrombolytic agents, bleeding:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Streptokinase is antigenic, and can cause immunologic sensitization and allergic reactions, particularly with repeat administration. Major reactions are rare, with anaphylaxis occurring in less than 0.5 percent of cases. However, less severe symptoms such as shivering, pyrexia, or rash may appear in up to 10 percent. The biologic efficacy of streptokinase is not reduced by an allergic reaction [",
"      <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/5\">",
"       5",
"      </a>",
"      ]. However, anti-streptokinase antibodies remain elevated for up to 7.5 years after treatment, suggesting that a suboptimal response and an allergic reaction may occur with retreatment many years after the first exposure [",
"      <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8634?source=see_link&amp;anchor=H17#H17\">",
"       \"Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction\", section on 'Streptokinase'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypotension may occur during streptokinase infusion (particularly if the infusion rate is increased above 500",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      per min). The fall in blood pressure usually responds to fluids, dopamine, or cessation or slowing of the infusion.",
"     </li>",
"     <li>",
"      Bleeding is the most common complication with minor bleeding at puncture sites occurring in 3 to 4 percent of patients. Major bleeding is much less common, and the risk of stroke is less than 1 percent in all patients and 1.6 percent in patients above the age of 70 [",
"      <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/7-9\">",
"       7-9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     GISSI-1 trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first large scale thrombolytic trial was GISSI-1 which randomly assigned 11,712 patients within 12 hours of a suspected acute MI to streptokinase (1.5 million units over 60 minutes) or no treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/10\">",
"     10",
"    </a>",
"    ]. At 21 days, overall in-hospital mortality was significantly lower among patients receiving streptokinase (10.7 versus 13 percent in the control group). The degree of benefit was related to time between onset of symptoms and streptokinase treatment; mortality was 8.2 versus 15.4 percent for patients treated within one hour, 9.2 versus 12 percent in those treated within three hours, and 11.7 versus 14.1 percent for treatment between three and six hours; there was no difference when patients were treated beyond six hours. The importance of time to presentation has been demonstrated in multiple other studies (",
"    <a class=\"graphic graphic_figure graphicRef53374 \" href=\"UTD.htm?30/18/31021\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link&amp;anchor=H69239847#H69239847\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\", section on 'Timing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The benefit from streptokinase was still present after a 10-year follow-up, with an absolute benefit of 19 lives saved per 1000 patients treated (",
"    <a class=\"graphic graphic_figure graphicRef68964 \" href=\"UTD.htm?23/51/24381\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/12\">",
"     12",
"    </a>",
"    ]. However, this benefit disappeared when only patients who were discharged alive were included. Thus, the long-term benefit only reflected the reduction in in-hospital mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     ISIS-2 trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar benefits were noted in ISIS-2, which randomly assigned over 17,000 patients presenting within 24 hours (mean five hours) with symptoms suggestive of an acute MI to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    alone, streptokinase alone, or the combination of aspirin and streptokinase [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/13\">",
"     13",
"    </a>",
"    ]. This study was the first to demonstrate the clinical efficacy of aspirin in reducing mortality in acute MI. Patients presenting within six hours had an overall mortality of 13.2 percent at five weeks. With aspirin, the mortality rate was lowered to 10.2 percent (a 23 percent reduction). There was a similar benefit with streptokinase. However, the combination of streptokinase plus aspirin resulted in a synergistic reduction in mortality down to 7.2 percent with the avoidance of disabling strokes.",
"   </p>",
"   <p>",
"    The early survival advantage seen with streptokinase and one month of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy was maintained during a 10-year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/14\">",
"     14",
"    </a>",
"    ]. As in GISSI-1, the long-term benefit only reflected the reduction in short-term mortality",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ALTEPLASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     Alteplase",
"    </a>",
"    (recombinant tissue-type plasminogen activator, tPA) is a naturally occurring enzyme (serine protease) produced by a number of tissues including endothelial cells. In contrast to streptokinase, it is fibrin-specific and fibrin-bound tPA has increased affinity for plasminogen [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/2,15,16\">",
"     2,15,16",
"    </a>",
"    ]. tPA is a poor enzyme in the absence of fibrin, but fibrin strikingly enhances the activation rate of plasminogen. Combination with fibrin allows tPA to attach to thrombus with resultant lysis; in comparison, non-fibrin-bound tPA in the systemic circulation does not extensively activate plasminogen.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     Alteplase",
"    </a>",
"    has a short half-life (three to four minutes). In contrast to streptokinase, alteplase results in less fibrinogen depletion and is not associated with allergic or hypotensive effects in contrast to streptokinase [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/17\">",
"     17",
"    </a>",
"    ]. Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (for at least 24 hours) is generally required as concomitant therapy to maintain vessel patency and to prevent reocclusion (",
"    <a class=\"graphic graphic_table graphicRef56744 \" href=\"UTD.htm?25/33/26140\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Initial trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the theoretical advantages of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    , two initial trials, GISSI-2 and ISIS-3, found no difference in efficacy between alteplase and streptokinase given with or without subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. The failure of these trials to show a survival benefit for alteplase over streptokinase raised questions about the use of subcutaneous heparin in these studies. Because alteplase and streptokinase affect the thrombolytic cascade differently, many believed that intravenous heparin was necessary to compare the efficacy of the two agents. This argument influenced the design of further studies, including GUSTO-I.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     GUSTO-I trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although several different dosing regimens have been designed for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    , an accelerated or \"front loaded\" regimen is currently most popular and appears to be superior to streptokinase as shown in the GUSTO-I trial [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. This regimen consists of a 15 mg intravenous bolus followed by 0.75",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (up to 50 mg) over the next 30 minutes and then by 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (up to 35 mg) over the following 60 minutes. The total dose is 100 mg over 90 minutes in a standard-sized patient.",
"   </p>",
"   <p>",
"    In GUSTO-I, 41,000 patients in over 1000 hospitals in 15 countries with an evolving STEMI presenting within six hours of symptom onset were randomly assigned to streptokinase (1.5 million units over 60 minutes) plus either subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (12,500 units BID) or intravenous heparin (5,000 unit bolus followed by 1,000 units per hour) or to accelerated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    with intravenous heparin [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/7\">",
"     7",
"    </a>",
"    ]. A fourth arm consisted of a combination of streptokinase and alteplase.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     Alteplase",
"    </a>",
"    was associated with a 1 percent absolute reduction in 30-day mortality compared to the streptokinase groups (6.3 versus 7.3 percent, 15 percent risk reduction) (",
"    <a class=\"graphic graphic_figure graphicRef71194 \" href=\"UTD.htm?43/35/44605\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/7\">",
"     7",
"    </a>",
"    ]. The benefit persisted at one year (9.1 versus 10. 1 percent) (",
"    <a class=\"graphic graphic_figure graphicRef65005 \" href=\"UTD.htm?14/4/14414\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/17\">",
"     17",
"    </a>",
"    ]. Combination therapy with alteplase and streptokinase showed a trend toward a worse outcome than with alteplase alone.",
"   </p>",
"   <p>",
"    The mortality benefit for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    was greatest in patients less than 75 years old and in those with anterior wall infarctions [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/7,17\">",
"     7,17",
"    </a>",
"    ]. However, virtually all subgroups, including patients who were older, had a nonanterior infarction or hypertension, or had a prior MI or CABG, showed a benefit from accelerated alteplase [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/8,20,21\">",
"     8,20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the angiographic substudy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    was associated with a significantly greater likelihood of TIMI grade III flow (ie, normal blood flow in the infarct-related artery) at 90 minutes (54 versus 30 to 33 percent in the streptokinase groups) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/9\">",
"     9",
"    </a>",
"    ]. This difference is thought to account for much of the improved outcome with alteplase, since the short- and long-term clinical benefits of thrombolytic therapy correlate only with the restoration of TIMI grade III flow, which enhances myocardial salvage (",
"    <a class=\"graphic graphic_figure graphicRef75629 \" href=\"UTD.htm?15/40/16013\">",
"     figure 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef70952 \" href=\"UTD.htm?9/52/10061\">",
"     figure 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/7,22,23\">",
"     7,22,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7786?source=see_link&amp;anchor=H3#H3\">",
"     \"Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy\", section on 'TIMI flow grade'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of myocardial salvage is illustrated by the observation that mortality was increased at 30 days and one year in patients with increased heart size (defined as an end-systolic volume index &ge;40",
"    <span class=\"nowrap\">",
"     mL/m2),",
"    </span>",
"    measured at catheterization 90 or 180 minutes after therapy&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The elapsed time between the onset of pain and the administration of thrombolytic therapy was also important, independent of the agent used [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/25\">",
"     25",
"    </a>",
"    ]. Early thrombolysis was associated with a lower mortality rate; thrombolytic agents given less than two hours after the onset of infarction yielded a 30-day mortality of 5.5 percent, versus 9.0 percent if administration was delayed until greater than four hours. The importance of time to presentation has been demonstrated in multiple other studies (",
"    <a class=\"graphic graphic_figure graphicRef53374 \" href=\"UTD.htm?30/18/31021\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link&amp;anchor=H69239847#H69239847\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\", section on 'Timing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Risk of bleeding and stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding is the primary complication of thrombolytic therapy and stroke is the greatest concern. Overall, there was a 1.8 percent incidence of severe bleeding in GUSTO-I [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/26\">",
"     26",
"    </a>",
"    ]. The incidence of moderate bleeding, defined by the need for transfusion but without hemodynamic compromise or need for an intervention, was 11.4 percent. Bleeding was most often procedure related, occurring with coronary artery bypass graft in 3.6 percent, and at the groin site of a percutaneous intervention in 2 percent. The most common site for spontaneous bleeding was the gastrointestinal tract (1.8 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link&amp;anchor=H69243091#H69243091\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\", section on 'Stroke'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The combinations of streptokinase plus intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , and streptokinase plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    were associated with a higher incidence of bleeding than the use of single agents. The presence of severe bleeding was associated with longer hospitalization and higher mortality at 30 days, as well as other adverse clinical outcomes such as recurrent ischemia, left ventricular dysfunction, arrhythmia, and stroke.",
"   </p>",
"   <p>",
"    The rate of stroke was 1.4 percent, which included intracerebral hemorrhage in 0.7 percent; most occurred within five days of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/27\">",
"     27",
"    </a>",
"    ]. The stroke was fatal in 41 percent and produced moderate or severe disability in 31 percent; the outcomes were worse with intracranial hemorrhage. Patients with a previous transient ischemic attack or stroke were at particularly high risk (5.5 and 6.9 percent, respectively). Other factors associated with an increased incidence of stroke include weight less than 70 kg, blood pressure above",
"    <span class=\"nowrap\">",
"     170/95,",
"    </span>",
"    and aggressive intravenous heparinization.",
"   </p>",
"   <p>",
"    The incidence of stroke was higher with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    and the combination of streptokinase and alteplase, particularly in patients over age 70 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/7,8,27\">",
"     7,8,27",
"    </a>",
"    ]. However, when the combined end point of death and disabling stroke was analyzed, alteplase continued to have a net clinical benefit over streptokinase: the combined rate of death and nonfatal stroke at 30 days was 6.9 percent with alteplase versus 7.8 percent with streptokinase [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     COBALT trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;A faster",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    regimen using a double bolus was compared to front-loaded alteplase in patients with an acute MI. The trial, COBALT, was discontinued prematurely after 7169 patients were randomized because of adverse outcomes in the double bolus group, particularly in patients over 75 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/28\">",
"     28",
"    </a>",
"    ]. At 30 days the mortality was 7.98 percent for the double bolus group compared with 7.53 percent with front-loaded alteplase therapy. The 30-day incidence of total stroke (1.92 versus 1.53 percent), hemorrhagic stroke (1.12 versus 0.81 percent) and death or nonfatal stroke were also higher with double bolus therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Angioedema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orolingual angioedema occurs in 1 to 5 percent of patients treated with t-PA for ischemic stroke, and it is typically mild, and transient. Severe orolingual angioedema is rare but may cause partial airway obstruction and require emergent airway management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6570?source=see_link&amp;anchor=H549662#H549662\">",
"     \"Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use\", section on 'Angioedema'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38391?source=see_link\">",
"     \"An overview of angioedema: Pathogenesis and causes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are also case reports of anaphylactoid reactions to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY OF INITIAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 1994 meta-analysis from the Fibrinolytic Therapy Trialists' (FTT) Collaborative Group found that the absolute mortality benefit from thrombolytic therapy at five weeks was 3 percent for those presenting within six hours from symptom onset, 2 percent for those presenting within 7 to 12 hours, and a nonsignificant 1 percent for those presenting within 13 to 18 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/30\">",
"     30",
"    </a>",
"    ]. The net effect in major thrombolytic trials has been an approximately 30 percent reduction in short-term mortality to a value of 7 to 10 percent. A similar improvement in survival has been noted in community-based studies, although the absolute mortality is a little higher (about 14 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44361?source=see_link\">",
"     \"Epidemiology of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Accelerated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    produces an approximately 1 percent survival advantage compared to streptokinase [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The benefit from alteplase is greatest in patients less than 75 years old and in those with anterior wall infarctions [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/7\">",
"     7",
"    </a>",
"    ]. However, a consistent benefit is seen in virtually all subgroups, including patients who are older, have a nonanterior infarction or hypertension, or have had a prior MI or CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/8,20,21\">",
"     8,20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above in GISSI-1 and ISIS-2, the survival benefit persists at 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/12,14\">",
"     12,14",
"    </a>",
"    ]. However, the long-term benefit only reflected the reduction in short-term mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     RETEPLASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/25/30101?source=see_link\">",
"     Reteplase",
"    </a>",
"    (recombinant plasminogen activator, rPA) is a nonglycosylated deletion mutant of wild-type tPA. It has the kringle-2 and the protease domains of tPA, but lacks the kringle-1, finger, and growth factor domains of tPA [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/32\">",
"     32",
"    </a>",
"    ]. Reteplase is less fibrin selective and has a longer half-life than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Clinical trials have generally demonstrated similar outcomes with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/25/30101?source=see_link\">",
"     reteplase",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     RAPID I and II trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/25/30101?source=see_link\">",
"     Reteplase",
"    </a>",
"    was compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    in the RAPID I trial, which was an angiographic study involving 600 patients with acute myocardial infarction who were randomly assigned to one of four treatment arms [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/33\">",
"     33",
"    </a>",
"    ]. Although a 10 MU bolus of reteplase followed by a 10 MU bolus 30 minutes later was superior to alteplase in terms of a higher incidence of TIMI grade III flow, alteplase was not given in the front-loaded regimen described above that leads to higher patency rates.",
"   </p>",
"   <p>",
"    The RAPID II trial addressed this issue by comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/25/30101?source=see_link\">",
"     reteplase",
"    </a>",
"    (10 MU + 10 MU) to front loaded",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    (100 mg over 90 minutes) in 324 patients with acute myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/34\">",
"     34",
"    </a>",
"    ]. All patients received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    . Reteplase was associated with the following significant benefits:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A higher incidence of TIMI grade III flow at 60 (51 versus 37 percent) and 90 minutes (60 versus 45 percent)",
"     </li>",
"     <li>",
"      Fewer additional coronary interventions within the first six hours of treatment (13.6 versus 26.5 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There was, however, no significant difference in 35-day mortality (4.1 versus 8.4 percent) or the overall incidence of TIMI grade III flow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     GUSTO III trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The much larger GUSTO III trial compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/25/30101?source=see_link\">",
"     reteplase",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    in 15,059 patients presenting with an acute MI [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/35\">",
"     35",
"    </a>",
"    ]. At 30 days, there was no significant difference between the two drugs in mortality (7.47 versus 7.24 percent with alteplase), the incidence of stroke (1.64 versus 1.74 percent), or the combined end point of death or nonfatal, disabling stroke (7.89 versus 7.91). There was no difference in mortality at one year (11.2 versus 11.1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, GUSTO III was designed as a superiority trial and the results did not support this hypothesis. Furthermore, the trial did not prove equivalence between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/25/30101?source=see_link\">",
"     reteplase",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    . As noted above, there was a 0.23 percent increase in mortality with reteplase that was not statistically significant. The lack of significance could reflect insufficient study size to detect such a difference [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     INJECT trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/25/30101?source=see_link\">",
"     reteplase",
"    </a>",
"    was compared to streptokinase in the INJECT trial in which 6010 patients with an acute MI were randomly assigned to reteplase double-bolus administration (10 MU + 10 MU at 30 minutes) or streptokinase (1.5 MU over 60 minutes) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/37\">",
"     37",
"    </a>",
"    ]. The trial was designed to determine whether the effect of reteplase on survival was at least equivalent to that of a standard streptokinase regimen (ie, within one percentage point of the mortality rate). All patients received a bolus of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    followed by a maintenance dose of intravenous heparin for at least 24 hours.",
"   </p>",
"   <p>",
"    The primary end point of the trial was 35-day mortality, which was equivalent in the two groups (9.02 with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/25/30101?source=see_link\">",
"     reteplase",
"    </a>",
"    versus 9.53 percent with streptokinase). This satisfied the criterion for equivalency of the two regimens. Recurrent myocardial infarction, in-hospital stroke rates (1.23 versus 1.00 percent) and major bleeding events (0.7 versus 1.0 percent) also occurred with similar frequency. There were, however, several significant benefits associated with reteplase:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fewer cases of cardiogenic shock (4.7 versus 6.0 percent) or hypotension (15.5 versus 17.6 percent)",
"     </li>",
"     <li>",
"      A lower incidence of heart failure (23.6 versus 26.3 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TENECTEPLASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/39/14966?source=see_link\">",
"     Tenecteplase",
"    </a>",
"    (TNK-tPA) is a genetically engineered, multiple point mutant of tPA that has a longer plasma half-life allowing for a single intravenous bolus injection. It is also 14 times more fibrin specific and has an 80 fold higher resistance to inhibition by plasminogen activator inhibitor 1 (PAI-1) than standard tPA [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The trials described below showed that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/39/14966?source=see_link\">",
"     tenecteplase",
"    </a>",
"    was as effective as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    and was associated with a modest but significant reduction in noncerebral bleeding complications. In addition, tenecteplase is easier and faster to administer (only a single bolus because of its longer half-life) (",
"    <a class=\"graphic graphic_table graphicRef56744 \" href=\"UTD.htm?25/33/26140\">",
"     table 1",
"    </a>",
"    ). These advantages have made tenecteplase the fibrinolytic agent of choice in many hospitals in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     TIMI 10A and 10B trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TIMI 10A trial was a dose ranging phase I trial in 113 patients designed to assess the pharmacokinetics, safety, and efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/39/14966?source=see_link\">",
"     tenecteplase",
"    </a>",
"    in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/39\">",
"     39",
"    </a>",
"    ]. Tenecteplase was given over 5 to 10 seconds as a single bolus of 5 to 50 mg; its half-life was 17 minutes (compared to 3.5 minutes for tPA is 3.5 minutes).",
"   </p>",
"   <p>",
"    TIMI 10B compared the efficacy of two doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/39/14966?source=see_link\">",
"     tenecteplase",
"    </a>",
"    (in an attempt to determine the optimal dosing regimen) with that of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    in 886 patients presenting within 12 hours of symptom onset [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/40\">",
"     40",
"    </a>",
"    ]. Patients were randomly assigned either 30 or 50 mg of tenecteplase over 5 to 10 seconds or 100 mg of tPA in a front loaded regimen over 90 minutes. The primary end point was the percentage of subjects with TIMI III flow in the culprit artery at 90 minutes after the start of treatment. Early in the trial, the 50 mg dose of tenecteplase was discontinued because of increased intracranial hemorrhage and was replaced by a 40 mg dose.",
"   </p>",
"   <p>",
"    The rate of TIMI III flow at 90 minutes was the same with the 40 mg dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/39/14966?source=see_link\">",
"     tenecteplase",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    , but significantly lower with the 30 mg dose of tenecteplase (54 percent). Dose responses were observed for serious bleeding (1.9 to 11.5 percent) and intracranial hemorrhage (1.9 to 3.8 percent) with tenecteplase, but were lower after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    doses were reduced and when titration of heparin was started at six hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     ASSENT-1 trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;To assess the safety of several doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/39/14966?source=see_link\">",
"     tenecteplase",
"    </a>",
"    , the ASSENT-1 trial randomly assigned 3235 patients to doses of 30, 40, or 50 mg [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/41\">",
"     41",
"    </a>",
"    ]. Based upon the results of TIMI 10B, the 50 mg dose was subsequently discontinued. The safety profile was similar to that observed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    ; there was no difference in the incidence of total stroke (1.5 percent for 30 and 40 mg), intracranial hemorrhage (0.94 and 0.62 percent), death (6.4 percent), or severe bleeding (2.8 percent) among the treatment groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     ASSENT-2 trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ASSENT-2 trial directly compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/39/14966?source=see_link\">",
"     tenecteplase",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    in 16,949 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/42\">",
"     42",
"    </a>",
"    ]. At 30 days, there was no difference in mortality (6.2 percent in both groups), overall stroke rate (1.8 versus 1.7 percent with alteplase), or the rate of intracerebral hemorrhage (1 percent in both groups). However, the rate of noncerebral bleeding complications (26.4 versus 29 percent) and need for transfusion (4.3 versus 5.5 percent) were significantly lower with tenecteplase. The improved safety profile of tenecteplase may reflect only minimal depletion of fibrinogen and weight-adjusted dosing (",
"    <a class=\"graphic graphic_table graphicRef56744 \" href=\"UTD.htm?25/33/26140\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The mortality at one year remained the same with the two agents (10.2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/43\">",
"     43",
"    </a>",
"    ]. However, the 30 day and one year mortality among patients treated more than four hours after the onset of symptoms was lower with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/39/14966?source=see_link\">",
"     tenecteplase",
"    </a>",
"    (7 versus 9 percent and 12 versus 14 percent).",
"   </p>",
"   <p>",
"    The ASSENT-3 trial, which also assessed the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/39/14966?source=see_link\">",
"     tenecteplase",
"    </a>",
"    with a glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor, is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     LANOTOPLASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lanoteplase (nPA) is a deletion and point mutant of wild-type tPA. The increase in hemorrhagic stroke limits the clinical use of lanoteplase [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY OF LATER TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A review of 38 trials involving therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/25/30101?source=see_link\">",
"     reteplase",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/39/14966?source=see_link\">",
"     tenecteplase",
"    </a>",
"    , and lanoteplase found that the efficacy and safety were similar to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    and these agents were more convenient to use because of bolus administration [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/46\">",
"     46",
"    </a>",
"    ]. From a regulatory point of view, only tenecteplase and lanoteplase have demonstrated equivalence to alteplase and have an equivalency rating.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/39/14966?source=see_link\">",
"     Tenecteplase",
"    </a>",
"    (TNK-tPA) is the easiest fibrinolytic to use (single bolus) and, as shown in ASSENT-2, is associated with a significantly lower rate noncerebral bleeding complications and need for transfusion compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef56744 \" href=\"UTD.htm?25/33/26140\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/42\">",
"     42",
"    </a>",
"    ]. These advantages have made tenecteplase the fibrinolytic agent of choice in many hospitals in the United States. In contrast, lanoteplase was associated with an increase in hemorrhagic stroke in InTIME-II (1.12 versus 0.64 percent) that has limited its clinical use and, in GUSTO III,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/25/30101?source=see_link\">",
"     reteplase",
"    </a>",
"    may not have been equivalent to alteplase.",
"   </p>",
"   <p>",
"    Although combination therapy with a half-dose of a fibrinolytic therapy and a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor was associated with fewer ischemic events than fibrinolytic therapy alone in GUSTO V and ASSENT-3, there was no mortality benefit and an increased risk of bleeding, particularly in older adults [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. We do not recommend this combined regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     GP IIB/IIIA INHIBITORS AND REDUCED DOSE FIBRINOLYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an attempt to increase the speed and degree of reperfusion, an alternative regimen has been proposed consisting of a reduced dose of a fibrinolytic drug and a glycoprotein (GP)",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor. A number of relatively small angiographic studies suggested an increased incidence of early TIMI grade III flow; these studies included TIMI-14 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/50-53\">",
"     50-53",
"    </a>",
"    ], SPEED [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/54\">",
"     54",
"    </a>",
"    ], INTRO AMI [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/55\">",
"     55",
"    </a>",
"    ], ENTIRE-TIMI 23 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/56\">",
"     56",
"    </a>",
"    ], and INTEGRITI [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/57\">",
"     57",
"    </a>",
"    ]. Clinical efficacy and safety were more completely tested in two large trials: GUSTO V and ASSENT-3. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/31/19961?source=see_link&amp;anchor=H53#H53\">",
"     \"Early trials of platelet glycoprotein IIb/IIIa receptor inhibitors in coronary heart disease\", section on 'Combined therapy with fibrinolytics and GP IIb/IIIa antagonists'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     GUSTO V trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The GUSTO V trial randomly assigned 16,588 patients in the first six hours of an evolving STEMI to half-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/25/30101?source=see_link\">",
"     reteplase",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    or standard dose reteplase [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/47\">",
"     47",
"    </a>",
"    ]. All patients were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , although the heparin dose was reduced in those receiving abciximab. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no difference in the mortality between the two treatments at 30 days (5.6 versus 5.9 percent for standard dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/25/30101?source=see_link\">",
"       reteplase",
"      </a>",
"      ) or at one year (8.4 in both groups) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Combination therapy reduced the incidence of nonfatal reinfarction (2.3 versus 3.5 percent); this difference was primarily due to a lower incidence of ECG changes as assessed by unblinded investigators. Combination therapy also reduced recurrent ischemia (11.3 versus 12.8 percent) and the need for urgent revascularization at six hours (5.6 versus 8.6 percent) or seven days (25.4 versus 28 percent). These advantages were more pronounced among the subset of patients with diabetes [",
"      <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/59\">",
"       59",
"      </a>",
"      ]. It could be speculated that the lower rate of adjunctive intervention with combination therapy failed to optimize outcomes in this arm of the trial.",
"     </li>",
"     <li>",
"      The overall rates of intracranial hemorrhage were the same in the two groups. However, combination therapy was associated with a significant increase in intracranial hemorrhage among patients over the age of 75 (2.1 versus 1.1 percent). Combination therapy was also associated with increases in the risk of other bleeding events and transfusion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A post hoc analysis confirmed that the risk of intracranial hemorrhage in GUSTO V was age-dependent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/48\">",
"     48",
"    </a>",
"    ]. When age was stratified at five-year intervals, combination therapy was associated with a lower risk of hemorrhage in patients age 65 and under and a higher risk in patients age 75 and older.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     ASSENT-3 trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ASSENT-3 trial randomly assigned 6095 patients with an acute STEMI to one of three regimens: full dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/39/14966?source=see_link\">",
"     tenecteplase",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    for up to seven days, half-dose tenecteplase plus both weight-adjusted low-dose unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    for 12 hours, or full dose tenecteplase plus weight-adjusted unfractionated heparin for 48 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/49\">",
"     49",
"    </a>",
"    ]. The primary end point (30 day mortality, in-hospital reinfarction, or in-hospital refractory ischemia) was less common in the first two groups compared to those receiving full dose tenecteplase plus unfractionated heparin (11.4 and 11.1 versus 15.4 percent).",
"   </p>",
"   <p>",
"    However, as in GUSTO V, combination of half-dose fibrinolytic plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    and unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    had no survival advantage compared to full dose fibrinolytic therapy with unfractionated heparin at 30 days (6.6 versus 6.0 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/49\">",
"     49",
"    </a>",
"    ] or at one year (9.3 versus 7.9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/60\">",
"     60",
"    </a>",
"    ]. In addition, the rate of bleeding episodes and the need for transfusion were significantly increased with combined therapy.",
"   </p>",
"   <p>",
"    There was no benefit and may even have been harm from combined therapy in patients over age 75 and in diabetics. At one year, there was a significant increase in mortality in diabetic patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    (17 versus 10 percent in diabetics not receiving abciximab) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     OTHER THROMBOLYTIC DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three other thrombolytic agents have been evaluated but are not used clinically for acute STEMI in part because of unfavorable features such as antigenicity (anistreplase and streptokinase) or nonselective plasminogen activation (urokinase).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anistreplase (APSAC) has an inserted p-anisoyl group to protect the catalytic center of the plasminogen-streptokinase complex, thereby preventing premature neutralization. This complex has a significantly longer half-life than streptokinase (90 to 100 minutes versus 18 to 23 minutes), which allows anistreplase to be given as an intravenous bolus typically consisting of 30 units over two to five minutes. Its efficacy and incidence of side effects is similar to streptokinase [",
"      <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/2,3\">",
"       2,3",
"      </a>",
"      ]. Like streptokinase and staphylokinase, anistreplase in antigenic and repeated administration within one year should be avoided. Anistreplase is no longer available.",
"     </li>",
"     <li>",
"      Urokinase is a nonselective plasminogen activator that has no specific affinity for fibrin; as a result, it activates fibrin-bound and circulating plasminogen indiscriminately [",
"      <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/2\">",
"       2",
"      </a>",
"      ]. Urokinase is currently being manufactured but is used only in the management of pulmonary embolism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There have been several trials, including LIMITS [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/61\">",
"     61",
"    </a>",
"    ], SESAM [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/62\">",
"     62",
"    </a>",
"    ], COMPASS [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/63\">",
"     63",
"    </a>",
"    ], PATENT [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/64\">",
"     64",
"    </a>",
"    ], and TAUSA [",
"    <a class=\"abstract\" href=\"UTD.htm?14/27/14778/abstract/65\">",
"     65",
"    </a>",
"    ], in which a recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) was evaluated in patients with an acute myocardial infarction or unstable angina. In COMPASS, the largest of these trials, saruplase with associated with a significant reduction in all cause mortality compared to streptokinase (5.7 versus 6.7 percent). Hemorrhagic strokes were more common among saruplase treated patients (0.9 versus 0.3 percent) while thromboembolic strokes were more common with streptokinase (0.5 versus 1 percent).",
"   </p>",
"   <p>",
"    Dose-finding trials are underway examining the efficacy of a new lytic agent (BB10153) that acts only on clot-bound thrombin. The hypothesis is that BB10153 will be associated with lower rates of intracranial hemorrhage since there should be no clot-bound thrombin in the central nervous system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Despite the emphasis on catheter-based revascularization strategies as treatment for ST elevation MI, fibrinolytic therapy remains important as many hospitals cannot offer acute percutaneous coronary intervention and as transfer times to hospitals may be in excess of the currently recommended",
"      <span class=\"nowrap\">",
"       AHA/ACC",
"      </span>",
"      standards.",
"     </li>",
"     <li>",
"      Streptokinase is the most widely used fibrinolytic agent worldwide, due to relatively low cost as well as a reasonable efficacy to safety ratio. While it is less efficacious than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      , it has a lower risk of intracranial hemorrhage and a lower cost.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/39/14966?source=see_link\">",
"       Tenecteplase",
"      </a>",
"      (TNK-tPA) is the fibrinolytic agent of choice within the United States, Canada, and many European countries. It is as effective as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      while offering a decrease in the risk of non-cerebral bleeding. Furthermore, it is easier to administer and lacks antigenicity.",
"     </li>",
"     <li>",
"      Significant limitations of fibrinolytic therapy, when compared to primary percutaneous coronary intervention, include: failure to obtain TIMI grade 3 flow in a high percentage of patients; vessel reocclusion; and a small, but significant risk of intracerebral hemorrhage, of which half may prove fatal.",
"     </li>",
"     <li>",
"      Combination therapy with fibrinolytic agents and glycoprotein inhibitors is not recommended due to the lack of mortality benefit and the increased risk of bleeding.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/1\">",
"      Wong GC, Morrow DA, Murphy S, et al. Elevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 substudy. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction. Circulation 2002; 106:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/2\">",
"      Anderson HV, Willerson JT. Thrombolysis in acute myocardial infarction. N Engl J Med 1993; 329:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/3\">",
"      Marder VJ, Sherry S. Thrombolytic therapy: current status (1). N Engl J Med 1988; 318:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/4\">",
"      Simoons M, Krzemi&ntilde;ska-Pakula M, Alonso A, et al. Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI-SK study. Eur Heart J 2002; 23:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/5\">",
"      Tsang TS, Califf RM, Stebbins AL, et al. Incidence and impact on outcome of streptokinase allergy in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA in Occluded Coronary Arteries. Am J Cardiol 1997; 79:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/6\">",
"      Squire IB, Lawley W, Fletcher S, et al. Humoral and cellular immune responses up to 7.5 years after administration of streptokinase for acute myocardial infarction. Eur Heart J 1999; 20:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/7\">",
"      An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med 1993; 329:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/8\">",
"      Holmes DR Jr, Califf RM, Topol EJ. Lessons we have learned from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries. J Am Coll Cardiol 1995; 25:10S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/9\">",
"      The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographic Investigators. N Engl J Med 1993; 329:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/10\">",
"      Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Lancet 1986; 1:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/11\">",
"      Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996; 348:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/12\">",
"      Franzosi MG, Santoro E, De Vita C, et al. Ten-year follow-up of the first megatrial testing thrombolytic therapy in patients with acute myocardial infarction: results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto-1 study. The GISSI Investigators. Circulation 1998; 98:2659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/13\">",
"      Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/14\">",
"      Baigent C, Collins R, Appleby P, et al. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ 1998; 316:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/15\">",
"      van Zonneveld AJ, Veerman H, Pannekoek H. Autonomous functions of structural domains on human tissue-type plasminogen activator. Proc Natl Acad Sci U S A 1986; 83:4670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/16\">",
"      Kalyan NK, Lee SG, Wilhelm J, et al. Structure-function analysis with tissue-type plasminogen activator. Effect of deletion of NH2-terminal domains on its biochemical and biological properties. J Biol Chem 1988; 263:3971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/17\">",
"      Califf RM, White HD, Van de Werf F, et al. One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial. GUSTO-I Investigators. Circulation 1996; 94:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/18\">",
"      GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Lancet 1990; 336:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/19\">",
"      ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. Lancet 1992; 339:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/20\">",
"      Brieger DB, Mak KH, White HD, et al. Benefit of early sustained reperfusion in patients with prior myocardial infarction (the GUSTO-I trial). Global Utilization of Streptokinase and TPA for occluded arteries. Am J Cardiol 1998; 81:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/21\">",
"      Labinaz M, Sketch MH Jr, Ellis SG, et al. Outcome of acute ST-segment elevation myocardial infarction in patients with prior coronary artery bypass surgery receiving thrombolytic therapy. Am Heart J 2001; 141:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/22\">",
"      Simes RJ, Topol EJ, Holmes DR Jr, et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Circulation 1995; 91:1923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/23\">",
"      Ross AM, Coyne KS, Moreyra E, et al. Extended mortality benefit of early postinfarction reperfusion. GUSTO-I Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Trial. Circulation 1998; 97:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/24\">",
"      Migrino RQ, Young JB, Ellis SG, et al. End-systolic volume index at 90 to 180 minutes into reperfusion therapy for acute myocardial infarction is a strong predictor of early and late mortality. The Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I Angiographic Investigators. Circulation 1997; 96:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/25\">",
"      Newby LK, Rutsch WR, Califf RM, et al. Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators. J Am Coll Cardiol 1996; 27:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/26\">",
"      Berkowitz SD, Granger CB, Pieper KS, et al. Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators. Circulation 1997; 95:2508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/27\">",
"      Gore JM, Granger CB, Simoons ML, et al. Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. Circulation 1995; 92:2811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/28\">",
"      A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction. The Continuous Infusion versus Double-Bolus Administration of Alteplase (COBALT) Investigators. N Engl J Med 1997; 337:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/29\">",
"      Purvis JA, Booth NA, Wilson CM, et al. Anaphylactoid reaction after injection of alteplase. Lancet 1993; 341:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/30\">",
"      Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet 1994; 343:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/31\">",
"      Furman MI, Dauerman HL, Goldberg RJ, et al. Twenty-two year (1975 to 1997) trends in the incidence, in-hospital and long-term case fatality rates from initial Q-wave and non-Q-wave myocardial infarction: a multi-hospital, community-wide perspective. J Am Coll Cardiol 2001; 37:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/32\">",
"      Wu Z, Van de Werf F, Stassen T, et al. Pharmacokinetics and coronary thrombolytic properties of two human tissue-type plasminogen activator variants lacking the finger-like, growth factor-like, and first kringle domains (amino acids 6-173) in a canine model. J Cardiovasc Pharmacol 1990; 16:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/33\">",
"      Smalling RW, Bode C, Kalbfleisch J, et al. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators. Circulation 1995; 91:2725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/34\">",
"      Bode C, Smalling RW, Berg G, et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators. Circulation 1996; 94:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/35\">",
"      A comparison of reteplase with alteplase for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. N Engl J Med 1997; 337:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/36\">",
"      Topol EJ, Ohman EM, Armstrong PW, et al. Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial. Circulation 2000; 102:1761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/37\">",
"      Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. International Joint Efficacy Comparison of Thrombolytics. Lancet 1995; 346:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/38\">",
"      Keyt BA, Paoni NF, Refino CJ, et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci U S A 1994; 91:3670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/39\">",
"      Cannon CP, McCabe CH, Gibson CM, et al. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation 1997; 95:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/40\">",
"      Cannon CP, Gibson CM, McCabe CH, et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation 1998; 98:2805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/41\">",
"      Van de Werf F, Cannon CP, Luyten A, et al. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators. Am Heart J 1999; 137:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/42\">",
"      Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators, Van De Werf F, Adgey J, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999; 354:716.",
"     </a>",
"    </li>",
"    <li>",
"     Data presented at the 22nd Congress of the European Society of Cardiology, Amsterdam, August, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/44\">",
"      den Heijer P, Vermeer F, Ambrosioni E, et al. Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction: a double-blind, randomized angiographic trial of lanoteplase versus alteplase. Circulation 1998; 98:2117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/45\">",
"      InTIME-II Investigators. Intravenous NPA for the treatment of infarcting myocardium early; InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction. Eur Heart J 2000; 21:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/46\">",
"      Llevadot J, Giugliano RP, Antman EM. Bolus fibrinolytic therapy in acute myocardial infarction. JAMA 2001; 286:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/47\">",
"      Topol EJ, GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001; 357:1905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/48\">",
"      Savonitto S, Armstrong PW, Lincoff AM, et al. Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction. Dichotomous response as a function of age in the GUSTO V trial. Eur Heart J 2003; 24:1807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/49\">",
"      Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001; 358:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/50\">",
"      Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation 1999; 99:2720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/51\">",
"      de Lemos JA, Antman EM, Gibson CM, et al. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial. Circulation 2000; 101:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/52\">",
"      Gibson CM, de Lemos JA, Murphy SA, et al. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. Circulation 2001; 103:2550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/53\">",
"      Antman EM, Gibson CM, de Lemos JA, et al. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Eur Heart J 2000; 21:1944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/54\">",
"      Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Circulation 2000; 101:2788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/55\">",
"      Brener SJ, Zeymer U, Adgey AA, et al. Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial. J Am Coll Cardiol 2002; 39:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/56\">",
"      Antman EM, Louwerenburg HW, Baars HF, et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation 2002; 105:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/57\">",
"      Giugliano RP, Roe MT, Harrington RA, et al. Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial. J Am Coll Cardiol 2003; 41:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/58\">",
"      Lincoff AM, Califf RM, Van de Werf F, et al. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. JAMA 2002; 288:2130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/59\">",
"      Gurm HS, Lincoff AM, Lee D, et al. Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial. J Am Coll Cardiol 2004; 43:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/60\">",
"      Sinnaeve PR, Alexander JH, Bogaerts K, et al. Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction. Am Heart J 2004; 147:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/61\">",
"      Tebbe U, Windeler J, Boesl I, et al. Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: influence of heparin on early patency rate (LIMITS study). Liquemin in Myocardial Infarction During Thrombolysis With Saruplase. J Am Coll Cardiol 1995; 26:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/62\">",
"      B&auml;r FW, Meyer J, Vermeer F, et al. Comparison of saruplase and alteplase in acute myocardial infarction. SESAM Study Group. The Study in Europe with Saruplase and Alteplase in Myocardial Infarction. Am J Cardiol 1997; 79:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/63\">",
"      Tebbe U, Michels R, Adgey J, et al. Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS Equivalence Trial. Comparison Trial of Saruplase and Streptokinase (COMASS) Investigators. J Am Coll Cardiol 1998; 31:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/64\">",
"      Zarich SW, Kowalchuk GJ, Weaver WD, et al. Sequential combination thrombolytic therapy for acute myocardial infarction: results of the Pro-Urokinase and t-PA Enhancement of Thrombolysis (PATENT) Trial. J Am Coll Cardiol 1995; 26:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/27/14778/abstract/65\">",
"      Ambrose JA, Almeida OD, Sharma SK, et al. Adjunctive thrombolytic therapy during angioplasty for ischemic rest angina. Results of the TAUSA Trial. TAUSA Investigators. Thrombolysis and Angioplasty in Unstable Angina trial. Circulation 1994; 90:69.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 99 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.181.191-9843F0D5B8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_27_14778=[""].join("\n");
var outline_f14_27_14778=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STREPTOKINASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      GISSI-1 trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ISIS-2 trial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ALTEPLASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Initial trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      GUSTO-I trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Risk of bleeding and stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      COBALT trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Angioedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY OF INITIAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      RETEPLASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      RAPID I and II trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      GUSTO III trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      INJECT trial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TENECTEPLASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TIMI 10A and 10B trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ASSENT-1 trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      ASSENT-2 trial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      LANOTOPLASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY OF LATER TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      GP IIB/IIIA INHIBITORS AND REDUCED DOSE FIBRINOLYSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      GUSTO V trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      ASSENT-3 trial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      OTHER THROMBOLYTIC DRUGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/99\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/99|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/18/31021\" title=\"figure 1\">",
"      Mortality and time to reperfusion in MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/51/24381\" title=\"figure 2\">",
"      Long term outcome streptokinase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/35/44605\" title=\"figure 3\">",
"      tPA versus streptokinase in MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/4/14414\" title=\"figure 4\">",
"      Accelerated t PA in acute MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/40/16013\" title=\"figure 5\">",
"      Mortality after thrombolysis based on TIMI flow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/52/10061\" title=\"figure 6\">",
"      TIMI flow and survival after thrombolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/99|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/33/26140\" title=\"table 1\">",
"      Thrombolytic regimens STEMI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38391?source=related_link\">",
"      An overview of angioedema: Pathogenesis and causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5018?source=related_link\">",
"      Anticoagulant therapy in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/31/19961?source=related_link\">",
"      Early trials of platelet glycoprotein IIb/IIIa receptor inhibitors in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44361?source=related_link\">",
"      Epidemiology of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7786?source=related_link\">",
"      Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22421?source=related_link\">",
"      Fibrinolytic (thrombolytic) agents in unstable angina and acute non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=related_link\">",
"      Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6570?source=related_link\">",
"      Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8634?source=related_link\">",
"      Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/46/16106?source=related_link\">",
"      Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=related_link\">",
"      The role of the vulnerable plaque in acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/40/28297?source=related_link\">",
"      Vascular endothelial function and fundamental mechanisms of fibrinolysis (thrombolysis)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_27_14779="Lab monitor PN infants";
var content_f14_27_14779=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Laboratory monitoring of infants receiving parenteral nutrition (PN)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Laboratory test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Frequency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        Blood",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Electrolytes: sodium, potassium, chloride, bicarbonate",
"       </td>",
"       <td class=\"sublist_other\">",
"        Daily until stable, then serially as indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Glucose",
"       </td>",
"       <td class=\"sublist_other\">",
"        Daily until stable, then serially as indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        BUN, creatinine, calcium, phosphorus, magnesium, alkaline phosphatase, liver function studies (bilirubin, alanine and aspartate aminotransferases)",
"       </td>",
"       <td class=\"sublist_other\">",
"        After the first week and then serially on an alternate week schedule as indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urine dipstick",
"       </td>",
"       <td>",
"        Daily until stable, then as indicated",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_27_14779=[""].join("\n");
var outline_f14_27_14779=null;
var title_f14_27_14780="ACC AHA HRS pacing syncope";
var content_f14_27_14780=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F73219&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F73219&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA/HRS guideline summary: Permanent pacing in hypersensitive carotid sinus syndrome and neurocardiogenic syncope",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class I - There is evidence and/or general agreement that permanent pacing is indicated in patients with hypersensitive carotid sinus syndrome or neurocardiogenic syncope in the following setting:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Recurrent syncope caused by spontaneously occurring carotid sinus stimulation and carotid sinus pressure that induces ventricular asystole of more than 3 seconds. (Level of Evidence: C)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class IIa - The weight of evidence or opinion is in favor of the usefulness of permanent pacing in patients with hypersensitive carotid sinus syndrome or neurocardiogenic syncope in the following setting:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Syncope without clear, provocative events and with a hypersensitive cardioinhibitory response of 3 seconds or longer. (Level of Evidence: C)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class IIb - The evidence or opinion is less well established that permanent pacing in hypersensitive carotid sinus syndrome and neurocardiogenic syncope are beneficial in the following setting:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Significantly symptomatic neurocardiogenic syncope associated with bradycardia documented spontaneously or at the time of tilt-table testing. (Level of Evidence: B)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class III - There is evidence and/or general agreement that permanent pacing is not indicated in patients with hypersensitive carotid sinus syndrome or neurocardiogenic syncope in the following settings:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; A hypersensitive cardioinhibitory response to carotid sinus stimulation without symptoms or with vague symptoms. (Level of Evidence: C)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Situational vasovagal syncope in which avoidance behavior is effective and preferred. (Level of Evidence: C)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Epstein, AE, DiMarco, JP, Ellenbogen, KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_27_14780=[""].join("\n");
var outline_f14_27_14780=null;
var title_f14_27_14781="Echinococcus species";
var content_f14_27_14781=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75863&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75863&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Echinococcus species, strains and genotypes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Species",
"       </td>",
"       <td class=\"subtitle1\">",
"        Strain/genotype",
"       </td>",
"       <td class=\"subtitle1\">",
"        Known intermediate hosts",
"       </td>",
"       <td class=\"subtitle1\">",
"        Infective to humans",
"       </td>",
"       <td class=\"subtitle1\">",
"        Disease in humans",
"       </td>",
"       <td class=\"subtitle1\">",
"        Known definitive hosts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Echinococcus granulosus",
"       </td>",
"       <td>",
"        Sheep/G1",
"       </td>",
"       <td>",
"        Sheep (cattle, pigs, camels, goats, macropods)",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Cystic (Unilocular)",
"       </td>",
"       <td>",
"        Dog, fox, dingo, jackal and hyena",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Tasmanian sheep/G2",
"       </td>",
"       <td>",
"        Sheep (cattle?)",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Cystic (Unilocular)",
"       </td>",
"       <td>",
"        Dog, fox",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Buffalo/G3",
"       </td>",
"       <td>",
"        Buffalo (cattle?)",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"       <td>",
"        Dog, fox?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Camel/G6",
"       </td>",
"       <td>",
"        Camels (sheep)",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Cystic (Unilocular)",
"       </td>",
"       <td>",
"        Dog",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Pig/G7",
"       </td>",
"       <td>",
"        Pigs",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Cystic (Unilocular)",
"       </td>",
"       <td>",
"        Dog",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Cervid/G8 and G10",
"       </td>",
"       <td>",
"        Cervids",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Cystic (Unilocular)",
"       </td>",
"       <td>",
"        Wolf, dog",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        ?/G9",
"       </td>",
"       <td>",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Cystic (Unilocular)",
"       </td>",
"       <td>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Lion/?",
"       </td>",
"       <td>",
"        Zebra, wildebeest, warthog, bushpig, buffalo, various Antelope, giraffe? Hippopotamus?",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"       <td>",
"        Lion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Echinococcus equines",
"       </td>",
"       <td>",
"        Horse/G4",
"       </td>",
"       <td>",
"        Horses and other equines",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Dog",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Echinococcus ortleppi",
"       </td>",
"       <td>",
"        Cattle/G5",
"       </td>",
"       <td>",
"        Cattle",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Cystic (Unilocular)",
"       </td>",
"       <td>",
"        Dog",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Echinococcus multilocularis",
"       </td>",
"       <td>",
"        Some isolate variation (see text)",
"       </td>",
"       <td>",
"        Rodents, domestic and wild pig, dog, monkey, (hors?)",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Alveolar (multivesicular)",
"       </td>",
"       <td>",
"        Fox, dog, cat, wolf, racoon-dog, coyote",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Echinococcus shiquicus",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"       <td>",
"        Lagomorphs (pika)",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"       <td>",
"        Tibetan fox",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Echinococcus vogeli",
"       </td>",
"       <td>",
"        None reported",
"       </td>",
"       <td>",
"        Rodents",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Polycystic",
"       </td>",
"       <td>",
"        Bush dog",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Echinococcus oligarthrus",
"       </td>",
"       <td>",
"        None reported",
"       </td>",
"       <td>",
"        Rodents",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Polycystic",
"       </td>",
"       <td>",
"        Wild felids",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Jenkins, DJ, Romig, T, Thompson, RC. Emergence/re-emergence of Echinococcus spp. --a global update. Int J Parasitol 2005; 35:1205. Copyright &copy;2005 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_27_14781=[""].join("\n");
var outline_f14_27_14781=null;
var title_f14_27_14782="Flow volume curve variations";
var content_f14_27_14782=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F65057&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F65057&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Flow-volume curve variations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 298px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Flow-volume curves from (A) a healthy person or from patients with (B) severe obstruction (emphysema), (C) severe restriction from interstitial disease (radiation fibrosis), (D) upper airways obstruction (tracheal stenosis), and (E) poor effort.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_27_14782=[""].join("\n");
var outline_f14_27_14782=null;
var title_f14_27_14783="Platelet adhesion and aggregation";
var content_f14_27_14783=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F76572&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F76572&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 502px\">",
"   <div class=\"ttl\">",
"    Platelet adhesion and aggregation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 482px; height: 219px; background-image: url(data:image/gif;base64,R0lGODlh4gHbAPcAAP/o0nOZmdbWVcv8/D8/GZ2cb6ywsJSZmYm4uP+fQMLm5nt7MT9BQcDh4bfLyxlKtLjNzXeIiLC6usr6+t7ZkJmZPb1xJqqqqri4bFZycj4xcv+uPZ5eT9escLhvSAAAAAAB/oCA/q60tP+8RP/dwXV70sTs7L+6kP/nWioyMv73qsfy8t+FMCwtJi4t7t7LQ8Tq6oCAgLTExH1LGZCqqrVtbjM8PL7c3FRUVLzW1v73nIqUlLvV1djYaWlsbI+NqwQCfv/HSkhTU7K/v8bx8VEwvmJ+fmqMjP/ZU/SjzcvMkqK2tpRZHe+POFMyZ39Ml0BLS6yurrPAwKfEtb/i4s59TR0WeJmS0U9Pd/a3t8evh1ZZWaqwyl5pbH5/tMj19Vk1Eb/f33B+fhARD7rT07GO09T6b/75de/vaFRT08Pp6XFxcZ+hoYJy4aKh/FpN7b+/TCAf/A8wzq3Dw6+3tqq+vrzY2LTCwh8T5rW/oNTOuP/Zs6Svr210dPj8jwcS7H+Pj+b9myh5hf/Tpqutrf3ohLbJyf/MmXZV6rC4uKS5ucW1p7CwsGN4ePzbkv///3J4eIKGhvjpoHWBgeWkWfPSgLqYROCmZR8jIzs1oIyhov3a6fvKpx8XCJnMzOf8af7qeTs+5VpfX//58+T9j0U49f+ZM7XW1vicPffDvPH8dOD8dv//ZpOwsP/7ZjOZZkxmZn9MWcj29r7b27XGxsn397rR0bnQ0H9/ch9fn8DAwP+zZp1egLbHx8Ll5f/z5sHk5MXu7r3a2sz+/v+/gLK9vbG7u/+sWW5CXc98Kf+hNxxWqF9fJjkiCy+Pb8bv7//Gjf+mTfDw8P+5c++PL//4YnykpNDQ0P/yX6+vRuDg4G1vck9PHy8ccP/ST+/vX+2gTY+PjwAA7IBmTX9mZbXY2Ke1tYBTI67MzMDA//fFc939kH9ybJ+qqZ/Iwn9MYX9jJbKtl/b7Zj8mTN+lPN/ttJ2ZuM+fX2xPsu/ITOrLW/7zcP/5aPqfM+/YgaiZhiH5BAAAAAAALAAAAADiAdsAAAj/AB8JHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNq3cq1q1eXAAYd2rXLlNmzaE2RPTQIwNe3cOMaHUUC2rG0ePOmPQaNxCi5HQHsOTRt1129Zo/tmnZoj1vAkL/+GnQYsWXLxwb9iizx1x5ilS9fPkZsz2bOqKXuKSu69eVde1IrJEEsmuvbaKMRIyG799FfhxLgHq43waHTvWkTX342wW7f0H3+Isa8Ol5iyCH/gibcuvUE0LJH/x8fc9QhvRvOslLP3ux69+1NvTeFzfKhv3IBTBONIu98tP/Fd9k0j5FnIEt7dOfdgmglENtbALDG4IRm7VLggRiO9IuE1QUIn3e7iIdVhBSWiJaFGab40SAK4jbfi/HBSFwCg2j1y354pYeXh0EE8aF88aHgoynKAJiXjmlhp+KSF42CI1pDAvljiSPEqNc0+FXFomgeEuldkTuKZhyTZEYEgG23ySjlmmq2iVs0F0IFQGhpWvmjmz96M9wxcZbpZ0EJmihocQ9CNcigiFpW45+MDrRHa0hY6eN6lAJZ6aWWmjJpfJGKVihTo3DIpZ1A9odppdUAWSWepiD5WpaNkv8JjX8Cdonoe2CuWSVa0DR1JmK2JupasGbBGSuZ1I2KVpEwVgqfs5k2u6aRohGz1KOiIcnqtqRy69qnxx4463D1CYtWubj1itR55rZ72SHhYojtZdKeGu299uab6ZSIgStUsnq956a+BONr8Hqm1mqZtfGONy+1rd6GrrdsnpWrsqb0h5a/PwEMsbuDdslww70B0GLA7EFb8MoHV8xvXgn02ZPHwHbrJcs4Z+zyzlHqNTLJnI2CJqJRosFBLLHggnQs5CCNDAeIRgPrzCBX7drPQAP2ZM3Ptoyp0VgAgUXSZCut9DZAFOD1vtNeCRTNKHed89xr27vqWRojhnXWbx3/mtZ8F3eKVt4Qs8KBBmJz0MTO63FghRUehJmX4PHtataiPLGrF+HMRUnxfD1P6Cq8fMP1y8mS1x0tB0BwgIbqhlvhxOv63nlZAiLa9DDXFadH9+9r2/5yWhyXnpWoFjP3IuscfG5WE2FDTblrF5+4EwBWZ0+czMZbtXvqvzMP/HoFpK368BvnNArqZ3VaL+zwj9+ye9PnNnX3Va0PsZ6WbSt+/EBKT/mQQTakKS0WHqhe6ppzP5kgj1itcZ7wGCeg5XhoF/jLiuZoJbe6/U9+5EOG2cqGDCtUgVV5IV1N/NY/K4EQgHRjFqnygrkMTuUXC9KWeprQOhhFSl++s9lZ/1i3OOLkDiwgkyAF3cU9GzIFbi6EHxac8EKcOUEDTcAU+kyxt5fQCXwwDGMV56czvRzDiVLB4QI9NB8d3g0DQKCdGA12Jyc4QXK5CtARV7LBj2VLiKUCYMIm2EYG1RCNTOlj+5L3Ow2obYwsQ0M3urCmXNXPLCoUiDbCEYNwXEMgugilLgYiSl1oQxulfAQD1oCQNYjiEdIopTSusQgLWCAZ1LClLalByDlCEoBB/FHomrNHRBaFfWkZplny2B4eZtGXqlqiKXgItbMoMy0JIAgbPvABBmDiA6PkJjfH8ElxfiAGMTDnI7p5EG2c8xG6MKcuGCDOZljAnBbwjhL3Wf9BCnXRmEX53t/CWAAqyocVrNgApRB60IU61FIMZVkPzKfFfmnyA+QUCCPK+YFHhOMDOBAIPUcJT3aukwExQClB0qmNgXBTIACYwQdmcBZumgUOYGhGMyoAzV/+sj7/6VITARoUDkGQmfC5G6WS1tPgrakAj6vmAiskkI+ysiAvjScDRApOUJoUo2vAwQfCMRBMhNSlHX3ELmQ6Ax3Z1BQzAMMMmvEBJuTFcgNrasEmaDncIAmDRP1NC2XYQX0p7VQRhShiQeg4K6hti6bYTDpjsE5uhvOcKfgAG7hKUq0KhJ3SMCkjPsAIgrwUe2yt6QfWQw0mcIOuM/CpXsM4Qb3/DDWwPGGh8lzIVNkibGfTa2zkLlOj0W5VF5m9LAMYsFnOenWrJ/0sdEUxBqx2tCypNctbmzEGJjBhphG02S97aSLA4nYoX7Qd8A4bUYSiAKHwja98H5rQ8TkOGeg74yMyKwrkdvWlBPFvOE750RSE08CiGCssP3BVWMbzA4ugRjLA8AEw4PKeH7AANT7QCTiw1beZKoAIy0biERbgmeNtW1pue96bjGKqLSysfHo7272mBUws6EY3WGAKy6HLFH+RBnUxioOWAhit3ESnOjHKzat+tKVeFacF6MpNe+Lzux+ALQcrhjOGlm8bScOF2cQcZrM5AQhOUNqJK6qmOqVl/xotDgoJ6JUy+B22oXiGb57bS985om24eeFNSDAB3YKokXfrCaJsRfy4R9atCQVI2pkdSdud4aWYca7JuNLSV70I7n2soDGIUZgXAvY4L+pSCCOkMRFpxICkBdk0g9yUqnw1dhvNEyOkzVfbBaU60ztJL3w2NTf4steh8012svPMbJYFgalmVIg01jAGKG8EmVyusSmgaoVcs+K9eQY3y77sgReaxVXNAXZPthy3uola2/bqNdL8mJBrpIABrObInGGM6Drny8sUhR0S6DuCShWgG7hgW5vpjBdBqxsn2NvyC8Xs0PfC4eJwgC8BFqBs+kZ0BgQ434xjoWKzyOyjZP/1CBQpCMnGFqAaHo+5fGDeMgxogG53g+w/Hx4T3Q4nr0tNOKbMOYZksOIDIT+VTC1gLwKstmL3pCle5o2YQ0qDASn45EewjZu8wajWq+shvOXjAQ3sjHPMySbPb6JII4GQFRSfLzdZUYEPcOPoBGCFAJhBgI1/QwBOZ0YF9M6MZjBDAKygq3xYUHhmGJ3CzVhAtKCtl0wyYgxryLdH9l0zEGugeXxWaMfry2eDTdTcJTeLw9c+EwkJruB4iZLnvPbu9cz9nnlHOivgEHlmVFgAncjyAlgwhsiPYQymcDoriG985LeAw80I0LwFlhbATnsMpQ0JFNGOF7z6G18MRUP/HGsc0YGbAgh01BVzds56liAPjF1eD8UbilBuLuD5g9c93fmu+wV8ION1xwwg939OZwoBOIBwEHWnQnV4kQzJgEH2hm8jMTRgJENVxAFYUHp6toEaqIHRAgQ9UGnzwT9pEQ3tRxO8028/FC1O4GiVwk0EsFPygXSm4H8LcE/Rt3SsIFNgsAAzMHzKx4Mz8IMscE/wkBfTlxbJUHzUgHIkcWgLAnSZcmejBiQaUG4z5B2YdoInQWe/I27ihwbJNnfxpXtOlw11l3c2aAkC8AEtYAlwsAACoHht2AIW4GECcE9gkA2Tl3BpQQ1U1glZVxK7Q30yVkW4sA30N3qM6IGU/6IBGDBHYFdBxcOFKeFHYHSIQFJQ9jJ3DaV7AjAGSJdlyxd83GAK2UBlLcACyoeKqsgCiYdR0kdy7EFl3NRcJLFy4aVe0RJRsNdtVahnVKhw/XQb7GeJJtFv49OCjdiM8tVsIhdqJDcfMkV0micSwsaLVcQKUMWBrABzzgiOMkcphyOCxWgK+oWMLWEdoCYfzkQwHSg/vWYWDGgKWGZOOABrIrEg3qeJlCJCY/c1IEiMZtFpy6GOLuGF8eNlN+eMDrlsv0N5yWBOncAELGASESdxesVQcfeQDslsXWBQqKdApsBiCAkSH8NGUYQpExWJ/4Zs3ghN/DJ9xIdRFnYWJv8hUG4WSC9pKbWnWHtGKcqwMkMpHz1gBSjGk+doGZZTiSe5jxiTM2igAULnkc0YlPEzb4AIBnaVFibRdrPnj3UDewi1DchglVe5gWQ5SR4QgjmTc6lnCpn0lMnYbspoKU6ABXUTj+Y4PPP2DTyWFw5RSrpwjQ6xNbuljfdSPi4YkECCAVcEBECgAU5QQJa5NJiZmUsDaGYBZ3SJEgo5N+SARWjZiN4AXwOHUAoVP++QCbxgGQ5hTl0VEQ8EHwkDSdyYNqXpjNiwgdHCAhhQYsI5QiOENOygAbR4Fub1mSWBFqmyTHnhdd/HCh5gQivDZ/EFjTkzSGvCC0UAAnLwB3j/wAvP1CCxCU6hxGoptQYxsFlsEAOMgAM4oHUDkY27eDBBQCkD53LgB5N8VnCJdZ02BkFoUY/oyJwn8X7ZtjJVADmXgp276Yh1UwN48Ae54Ayv8Aq5IAcgUAQ1YD0NkWTo9AhrAFLptFX0hAmZhQkF0W7tiCkihgFtGS3lA3r+GaEx6ZvAA1TtYaCmgKAmoaD3mWhNYAWxEIxOBTpmwQsgsAwZ+qQZ6gwPgAcgyhCyuU4sGl30JBCZ1aJRaBaNFQsagDiSOaa4gAxiRzBFmaMB2pdxqRc+CqQl0XbT2TKU+aA4OnraiS81AAK5AKWA+gp/8JqYdJ6mBV3stKWqlFYD/9FCLIMBUcWSHhCcuJanaKlt7hEL+OWVcjoSLGQ54HZjtLIeXdANcjQ3NPeNY/QjXvAAgQqouUCll2OoA5FZjLBNKJpWitqo7EiPerlYsMNnpzlfWAmPA3ob3TYtnToSGXmXMDqQlCJua+pel6qjsPMErvqqUDqoJkerAnEN30RPucpVXpqJLQOMXhOPlsqmKdY4ViCYywqVeMF9A2UWE1UFjlkw3Bkg2Kqt20qoFaELjKAL6dRgCcEgUKWYxTaObQo884gYzAOv8QoS2bgexHYvE9WYz+iNpdlsDRst/eqvGiqr6SgR24RRomCYB8FBOONYwbquHylbpuBYXTKxIf8ha5C1JpKEX5giAEywAEwgAPJxh3cIJAmYgAKQDATABE3HtMlwtMmQh0LLCtSQgGoSD34qstxqCuoQCIFACiShT45zMB/bkzFbtkBZO28Kpu+qFzYLEpyHMvlyRfdSd1kWfHBgCkSHeOY0A3DwAZLHgXWXt04HgxM5Bt+QfB/AU5gSD0/gAk36qlIqq6aAD2nQDvXgtX7gByipkYUFPUe6lzEHs+MokzMrVXjxth/xYswRC0gJI/SAUUaHikZnU3V3irHIdFFXeHxIKc3QCUBig/LxXXJld/HBpA+QvH9goRiqoRzqoWeRByUQCiDgAiXgBSVQAvagA5y7EczRBBz/cGZOEIkKCzvTWrryaGkQ27Zuq7oeIWz1wgFmaZ3R8l2xBVFz97d5xwpOl3F/2wn39wGIt3yLSynwMFOUQmEcRg2YwgZZ+6QbCp7iSZ5ocQyBwAVx8AfJu8F/EAdcoAMgrAMY0UJgtx42h2ZrFj8Yl3EItXFouQD7q6c+hQw8277uyxE+5yHgizSPgzRY2DXCK2VHN1P4Jx90pbsIrIA1+AGJux7Cux5/O1OEZQpM+qeBmgsgkAZngSSVoAmRG6jLAAKh4AVKoAIgrAKSQBH2mRYsoAHdVkQvmp/yYX5EV7tJx2cylXF71oqY8reBu6cqcxnJOjhnUbI3nBFQiBeQ/4lmZ6qx0YKDrGABz5e3MCiD69G/puDHmQy48tEJuDuUH2YK30BXxze764G1VvyqWPyhaWEPD6zKIIAHGZwGP6AE9tAGuNwGIRACbtAQ7yedTRALQBALp7qQQ0x3dod3hNd3C/B3gTd4e0cAh8e/q7XMjscKvhd5aMsyK+g4wbKch5wRQmqkReSiZkFXYMB7GTbEmaLOQauH6mx098R08pEMvud4pkBhM3BPLcBLZhGy/voAT7AXJZCtAe0FOqAH9lAKIKDBG6y8cZAOC4GYTcALhDpNjqMBgWmu+nJ7pEiDvLcAFAYGwCd8zLcAx6e4y1d8KO180Ke2C1dqyZkXnv8Zzhqhk2NLN98ABqI4BiStt6u1mkNsf3/b00zLCtzQCQtVuEj3XdG3xMwAJK0qsq8g0GnhDwVN1Q9QAmasA3Fg0ID6AHFAAiRQBrt81rz8CJrjnRKMB2xwZt3gkj3FTeeAf8q8f06nhv+HzMwAwwS4WgHo1wkIuLKlNGYhx2kxlzZ9EQrSKRHbb2KZM234x/aygh8C0Npq1WfRD4GQ1SL7AG1gxvbwB1qLyyDw0MkLAm7wKBTKvBmaC38gDgPdb7fZi7aHdJZMgzaIezu41zLV10QYhBXmg8Pnx+d7L/tqGT6aPoutEYpEw59Wp76VDMMHPFP92bNtFvoQCCEA1q//utVmnAapDMuvDMEgUAZM6qRgDAKECklkeFCkeIZpyAo2CAd1mA1xCHirdd94+Ld7aLrroanBYpLN3RCJbArLHWMsJ0jS5Cp9Ot6wCgKsbBZKsA6eHdAloAOSAALNq63O8MVg/AflHeETflcrmSmeSCk0GIpZRoosYIquyE2r2IqpKOOwSMowfRYGiReDbMMFjhE0Q3Uvmq8wlN6vGsYXbQp9GgdxMOJQisUfbA9yQNWwrbXeHagP4AV6RZakS6ysQJY9NbaIYcg/XhGJTHlrG0VKwAte8ARt/uZP8AMnBD9TrENn0doX+tqx7QQ9YwZmMATTC+JQGsZsYMZuQNpa/wvhYX3lYZ3d9bqgaQvmwbjNWThErbMwZe7cBTrThdMybFAEIi4HqL3BHPoHacALp9IEbODmrA7ncl4wbB2e4wkEnPkCfk4Kq7AK7ZDBqN3BH3zGcaDoEIzoAc3oUGrVv1VF4haPqSlfzV6s4iaTj20rTpnpD6E/YHpHS+kfrb0MgkDVryAIyyCeH8oKFf2doj7qyVvqRZDkeYEGFm0KdtQg+GEGq/AJn+AH9uAF2FsCkBsKJaAHZzza/lrln23sT6rZUSndRB5v6psXj20ZW2jtDTEvzvToBfPV4I7leHAC6J7nVC3u4nkCBGkWHgAE5WwKHPMJqiAP8uAHZ3AGFP9wBWmQwW9wBXqAB8b+AE5+7D3/2iAQD/CWqgiVn1Zp9JSSqtCEBk7QbXA5LSZI8eJ8Fp+Xs0bCC8S+8duKB3LQ4Vpf1ZSbFjpSpJwJzgchD2fgCq4A8zJP8yLe0KMunm+Q9YH6Bwyt3oCK5IjRj6IrH0K9kfp5rAVp6U6Q8noj9YjcHWKO8f6G9V8Ppc4g4ghP1YO6cPNOTBDBD2ewD/ugA4VQCItwBXMPAiAQB2/QBleQCiSg8d8NAogAua6toeIp9OU7PubHrsVafmNkNI9Dvmu7eohfESwkO6h7Gzr/+BEsBxwqB8IusmFc4mbBAh7gAWia8ocEEaBQCNkvCY7/4AiL0AYM7QKIUAapUAYVCvLOANsOTept7e6tIZ3wUcINnym1xgEEdECXGQuTVvy3AxCPBA4kWNDgQYQJFS5k2NDhQ4gRJU6k2HCaKVMeYlmxEsvjR1wgY4UkGSuTuD/LBL1i2dLlK0F//uRyxtJZLpkrX+4UtOyPuEwfNWgAUnRoLA8YMU6rWLCQI6h7BnEq06YUCBeI3lyVIwcEiAc7Xzl78EcpRlamUJhK25btW7dx4c6Nq6wtq7t52eLd29Yu3bkFOI4kXJIkBzSA0Z49S6zpY8iRJU+mXHniqGhnCyDzGFLkR9AfnxT5A0LOA9SpUXsNK/aBaZUve3r9U+SJ/0gPHlgsZhxtlOVDhzhxypIqSxlELkDEwfMG0R+xLf/wSsvYOgfOhDsj4wBYLl693+ei8YChvCXzGNSXL2B4o5UCb3nLt259RH1TJCzv59/f///KAEgAP/yq866KH57wQkEGvSAtOpb+SKMI5f7oCoTafqjCLQKtSwCA/wAoLoskSCzjjThAyAXCV3IpAqMNlDJwM47cI2kw97AYakcedyzqRyCB7HFIDbAoLJZtOBBvSRmbxC8BAKOUckoqAdyjw/mw7BCPFSHMBQ+lauCFlyo6NJDAPajcJAk22QShJgidAaEJ/DgAwonuCGQFO+1G4iC98gIFNDEmC52rGvoMPP9TSy2hqfJRSCOVlKErtVTUO0zZgI7FV6YzNEs0Jd2kDTk4fUUOXpw0pQAg4jP0VUxhlTVWWtNaa1Hrfpl0V157lRIaxtYClVFTlFEKBV5K5RRVYk3xRtWzHJ3UjU1Z/CMTzz5CBog89VR1VvD6EjdcVpCYdT5cGV2UKV/bdffdx4hR99u5FksLjTdZlLOJS429VEvHeI2jy+i+DG0k7hKtdWFwGXZYLmwUhhE/EOG1+GKMEQK2WY5NKWIZFpd5sUNqLEgGo2QswIgFC1go2YIqdNGFV2qtTbVjb9FtsmEmdR4WZ+t2yXhooi+uFEsk6A3CuxpULBiEeExZ+l9T8vn/4AOMOvng5GY+sMCCq8PuNY7WdnoAzAJNuY/nh9tmG9afMaq4aLrrnnSPAZUydj5skrYuXYx4cfqlXEC42UALZtitghmoacFrFq5mwpSrS/4gBZln5jWdOP5QDbU/8KgBaKXu89lt1OU63XSOzxTabthjpxKAzJpNF9ciwPocBDbqq+CDycfoxJQZgGfig2bAALuZaOL5AJMYYmCjXTdCsP56NwCwtEl/U/f+bVpPr29u2cs337JRLsL5dlME//y1keejZoxmkvlgBlPABgOMZmYY4/hxjEIXYfsAA4gmL9JhiWoLpNfpGJjADgXsfBOkYGQGkbeO/atpBGtJ4UaH/yswfCCEuzGF8O4HNq1d4xEDNCDdfoFB3izNXt+jIfg+RR8cmiIBuqpgD30okV/soj5+k5ha9GYKPIBMLMtA26XAhjylhHBrlPvAGATCQrsNgkCs01KMHNikW7UtjF+cGLG4yJhB/FCNa2wI3iDIi2qJZTr40drkMHK8MSRgDzj4AA6uWEDYHYNAwlJYjGxYQ9SJrz7HYGMjHWmQURwigVxi0Zc4dojfVFB7ELRdA4v4QE4yinyPJCUbf4FAjsHRVHMEGA99qMWcIfKQs4QWftJYSlw68heHgGF9WHeAOEaHlU/CZCOFeBbAtc6ToGRmLTNYn9flUpqN3MMxtURJL/+hDZppeiRmzLRMWYZzjEUkkG+mec5G/mIQguyQKiE0TKUcYxCuJOUmQ3lPfCbwQ+jkZyNHQQJosNM6eCjbS84WT2iQIJPTPBpjqnOpiNFSopjKEuC42c+FGEAEEhgCLRxwCx7MogEKMAERZGECawSACiZQQANukANbOIAWUjCGCAxwAZxGT6c75WlPffpToAZVqEMlalGNGtRxnGMGX6OGKWqAh5nA6SY/mcc5xnFUrGZVq1vtaVI6tLcEyvCTnhQr6cCKHw9wVa0+1ShHPQpSkZLUpChVKUtdClOZ0tSmOL3AY9ra0Y+GdKQmCIANPgAFKHzABoC4a0xnWtOb4hT/FpOlbGUte1nMZlazm+VsZz37WdDC4gI+8EEUDHBaEaSWDnRIhASMYYxilCAUpvFKKErQC0M4wAEQ4O0tbEEGMvCABznIgTCEMYsb3CAMYWgAFYABDF8oQA1qgIEJTBCMYBCBCCtYwRe+IItaTEC8AxjAMIZBXvFOoBay8C53ifAM7FoXBmpQgAJ88VwqNGC5yZ2FMOxAXOEC9xa34C0EdGuIXtCCFjK4BJYIycC1hRNuY9XSPUJ7YQz/9a2CJWlhD5vYxTY2r5Dlq183Cli4jhQQHziCCQZQCypM4gMReKlj9RrZC3hCxzvmcY99/GMgB1nIQyZykY18ZE/44AOl/z2tRlXLWtfCdghD4EIJSsAFBeNWtwX2LXCFS1zjIle5zHUudKVLXetiV7vc9S5400te86JXvOtt7wreG18TzLe+9wVGfvd7g/7+NwcBJsOAC3zgBC+YwflkdKPr0wEkR1rSntBwYOO64ha/OMYzrvGI94pTE7vV0g1YcQBkQd5arMAEK44AXh/76RxPWtazpnWtj4xYQpgWtU9u7WuLMWUp3EEGMshybnfb298Gd7jFPW5yl9vc50Z3utW9bna3293vhne85T3vANJL5y+4F77BkC997Ytf/YaBv/4FMA8ETGDeIlrBw5ZCgzsk1ktNlG3jTOZZIG1rgO+40iku9f+pX6xqVrv6xiVuysBDGoEPAMKkqFa1AiAeARuTGKcB53jHPT5kHOAg101OrQhW22spDyHYwy72lpHt5WWH2dlkjvaZqa3ma7dZ2xOAc7e/zd5w23nc5d4zuv8c6Ha/+9AOQPC8ZSCFev/N0VP/5qM/bmuHzwLiEjd4qll68YzDOtQoDikmxFDSrle8AREYwxI8jeOrx13uAMe1rp1scij7GtjCJjYttHxsCHRZ2WBu9pihbeZpp9nabM72m7ktZ/UCXdx41vO5+5zudQua0IaON9MTTW8pDMHe8yLjWyIcUUwlrZmKxM+/5z7prJsd7RS3K9vd/mocj33DEcCEXNP/btcbbAETb+fr641//CIrmcm7xjvKf61yvrcc8IL/MrPF/OwySxvN1V4ztt287Th7e86SFzrlzc1nP6sb0OwetLsLDW8De97pUJ9yB6h+f5xpAfmSdjjvfU/7lgq+4cM9hqsIh8OECPi/gwO+HMCELSDAjds/CZzA0VoykuO1KHu+leu7v+OyZKs+mTO87LM5xes+nXO88Pu5Orszcsuz8zM69UO69lO6zms6RaO/ISgGLUgbh6IXRNE3tSkiL4qbE5hAJDvABJy9BQzABnzAhQO1hjuxt+K9wZq4JbyrJRiDCHjCWDNCL5y7CyAEURiDC2y+DNw7lvM7Y/NAmCO8/+ujOcTbPpxjvO/juccTv8hbwaFzwaK7vKNjv82DP3m7wdDLQWNYBFSoOvwDmn4Dhyn4QiMbOCpUQK9jwizcQo3rqygUtTnAhB2owt9jQlsQA0zgQkg8xY8LQ0IYgy1gg7s7uTOEvjTswJcbPOubucPTvptbPO/buZ6DPHCbvBasPPTDvPXTPPfjvPizQdCbsmJ4LToAB2IZwtWjMGvsN+ugBHdARSKrtE78REpUuxojRS7UPQfoghSIKyWsxMaqgzE4gEzkRnm0NVWEBMOygW3AQL2TRQ5cw1oEwcLDvppLPO7LucYDP58bPz00vz5Mv8xLuvdbOmZ8ukJ8RmOQgP9EsL9F3EhT0L95FLJKQ0d1tEJ2rDF3hEex28SO4oMPUISRDEURQ6x4/EiajDRVNC022AZMYEU2yLuU20DpY0NbDEGBjMNdNMGDtMMUVMigY0GiszyHPEaIVMZBbEZDvMhEoIN/OBmOeZbSq0ZsxA9HrMkg0zCWdElQBMCYhIJM1L0U6AIOW0dxxCtNGAM+gDWyzEsiu0mSiwQGKKBIiEWgVEOXC7wPjLmAhENdLEGDrMNfxMNgLL9hfEE/jEFATEZBlD9CdMbXkgA+2IIxYIAOSERFPIszwqewNAVU8Ei99DENe8u4JMm5jKm6vMvcU0m2m4PYhMlOowVM6AO8bE3/4ewxvmQ+NgDN3+QDDYw+wpy+w3RDXBxBgpzDXkTBhMzDptxDYoTBh5zBiKzBz6NIzjyALhiDFoiE1IqH0esYsHowsoKgDnjE4eyxv8rN3VTL3vzNlDTAE0sBMUixcGRAx7LH4JzP4SzOV2StPrjHPjCHwaRFw2zDWxTBgZRDXjxBhARG8nNKPoRKY5TBQJTI8JQCc5gEUUiBKrKBPlitkjMALZBGjkwgSsgDA3XN/vzP+7zC3iTQ2+RPjrJLAJVLAZWpdhiDAq1RvUTQkoNFY+CDBVUsSDCHfixM6kPMN8xFEixIOvTFO1TB7GRID/1DZKTBZUywdvABKBiDyxGF/0ngA6xk0dRqshdVoPpgH6m7UwKZUSS10R/lgyCVzSGlhSLdT4poK0AYvj/lTYXDhEiAuz1NUkIYOeZjUikzB3tULB/YAQitUuikUKNkzC21Tg1dyMlsyA+9TDJ1gDqIgDQdAxvwgQOoyM7MSjpo0dOKAkLQAkogvR7EU2RilEug0Uelz4061FELUFHMK0bt0ULdKCHAgWMV0mSdKSEQAkcd1ppUUn38yTuwVCjAhOeBgj7YgX+00uis0KNsTC5dSuwUxqcsRjGdSgLbgS4AV0wQhR3YzKvESDi1qVuN1AtQT9KMUcZAhfjEVj591mgF1GmVgmpl1oloK09cWEW1sf9DvVaEnUdtNcN9fNAd2IZvDdcu0ARFAMgrlU4LRUrH7FKmdNcOhVfLREZF0IQuYIAxGAMoAIQ6mEgctEh+rdU4/VdCKL48GE2CNVhhzVhilYCJTVT8VLiLLcBmZYMx2LCXfNqMe8fiU1qNjVS7W1KfXM5Z9Mcd6IMtSAE1xQQG6III0ISTRVdQrc4MhcwN1U7KjMpZqAOaFQIUvRxxXQLwnD9ZfVOg9VcDwNWhjUAdK1oYnTpw6ICk5VpipVqrTUsdVThj0Foo5M8FrVxkFbHHetWtlVxU3FhKFdspdU4v04QIqFlwdVVR6AIxoAHaPYUspU4MVcrrjEwOJcZToF3/GhCDLhACw7ocIRhZRUhVzbRKn6VVWz1cgFVcHpuCE+iAxoWgxz0B+STdH9OozqVYrB0x0d3cZhUCUfBcaQVdmtoCIRhd7v1C0w1bNExdoTRZve2C4bUB/Q0bV9XfLmgEAA5gADYCAi5gAy5gAU7gRoAF/bUBNb2aBj7eka0DVP3OMhVcziTc50Vc9wWyPDgBLbgESrje+gAHSrgELTiByH1fINMo80VfhlVfY2BfqY1YEWgBQIDhih2xSGiBDmZhCYxf55vfoCzXTi1KaUOHVlhiBQ7gAyZgKNgCA25iAV7iVkCHMI1ZeRVRDN5X5w1a6E3cLgRiI9QoHNbh8H2s/x6uYYnQqHdE48vNuB0Ygx8m4+MTYsFkzk19zglF4tu90KSEswwwArol1XflTqn0TqpcXvH04n5tMg6WXjvePzc+ADguScydYzaOCI36ALK72jj2tA+o40kuZY7DhBQwZVW+uk7+ZMvF5LAbZfKN2Dl25c/tTb0ag3CQ5FXuZVlDgKvxZWGuNQOo5UueTU/T5Vlu4x625fTF5ZpqgRjg5WGu5iEzgqs5Amve5khs5mMOVL2S5mXmZPZ15hiGZhF4VmrmZnbWscT6ACFoZ3l2zXL+5oatKXXWRAM0X3Pe4VfbAihY53m25gfGhIE+aAPgZ3uWYREA6HGGCANogUno5/801itI8OExPuhttgYCQgCNlueInuiFRueLfuiHMABMAASKDuVXiwRMEOiPXuUMICAjiGl2RmmVHmnMFQGXNmmHMIAP4IOVhmVPYwNZtultLt6rgQKk3magFmqdDjuj9umGMGpRc1qWvrEPYIOMbupVfuCrGQOvrmarHmpkxr2t1meKiAFMuOocJWrcg56uHmtVniy6rma2dmtQhusbk+vHuGi9fuWzvrEWWIO5vutJtmvE9mXANmtwhqzCVuuJYN/AvuWdNgAowIHDXmwgVmzOVmXKdux7tqnMlmyJ2IItqOxnvuyQ2+zP5l7Pfu1JRm3VPmfW1uzHoG3RZmgDKGn/2S7l2P5tINbtqH671s7t1N5tdDaAGPBh4bbj4H5u7iVu8M1qyDrupqBurOZryDoAOpbuzoYF8B7u5C5u3MPuitDutx5sEhvl8X7f6H7vjFXvvWZvm0JviqBvwX7svXpH+Sbd+P7vYdVvyw47A8DvyS7v6ubuvZJmAefaAH9wJCXw1TZwBD9tBd9u+76pwpbwjI1wD59PCrdtC8ft7M7w9ebvmwq5EMdWEG/x1hxxf76xC48IGa9oEstsGH/UF99xsrxx675vE09vFK9vFb+ADvfxGu1xJf9IIGfwAx/y/C7y/R7tm4KeJjdQJs9ybnzyDa9xiPDyI99qLh9OBPDo/zIXTjG3cjB/iDXn7alOczkX7jdf7jZ3iDq/bLZ27Tnvc5vO8xI3bRun8gJ/O9/2c0Sna0A3bilP8Nqe8esO6ETfsQAIADRHgACwBoAzghTQ9EmzhhSoab7tsRSIZyDjdE+fdElb9PNudAx/dBwXcj7ncsOqaU/A5gwAOFj4gACQtQD4APFG0R6DBVv/sQCABTRX9UhjdRp39YhobPMmbMNWdmw2aE9AUY8urFL3aGuAghSwgZru9m+vaQSAhW/X5l3vdR0rd20+do/OAPHW9hTI9V8P9g8Y9po+9iPw9nafrDOHhV4vd0sH+CMwgiNA9ltH+EmH9gXf8Mh+jOaG9f8gj+hpVnZPUNMzVyxPOALFEgLFAmZMgAUosAGQF3kb8ISdhAVwtYZ057ExMOjEygBgPnmRN/cPMIJ6v/Z757HL8YRdH4O+RQAjUNNKB3ZPqPdfV9NQ/4Bcv1llj3jlvmxxfgzvlngo11qL93hYmGltNqzJUlOOHgMhkPmwH3sE4OgUEHlgb/kdSywEePkU4HhyzwAbAFeAN3ph5/lUbnmP7/V0z3mkh+d1f3mOz3VVr/qoN3Ct9asPsPoNP2plD3un1/nK2ni0fR7LT9tfT/vJOnZe5zFs9nhsdnuUH4MMmOm7t/ce6/mWb31eB3xgz3l3fp4PSPZEB2rHV3FZ9qv/MWCDxPc074ZpOQdXwfeEmbaBANj3AICCIwiAm13+5nf6m8X5QWb7dYdgT7gaa6+iAND6nM/7HWP9z3f9TK8im099Ssd+ZTeA3v/9Vwt+QYdoHHZ/vVrjWS9zbK79HYOFBwYIGwgwffiAydrAggc9WbNRcMwRWB8CeKpY0WEGTxgrGimY4gOsACA9fbRY8UMKTxIprlQ50ZOQD2OggBQJy+SYD0dM8uzp8yfQoEKHEi1q9ChSTwZaABpCy8EtHrMaKDBBRNaAAbVWmFDQ4EYOWw5oSTEmIlKLCxcesW3r9i1ctksnOYUqlapVrFq5egUrlqxZSGkvJC1s+DDixIoX/zNejCDAR2tEEchsbPky5swm59aNOrXq1axbu34NO7asCMFq47JmbWCLqM53Qesd3dc0YBFbcKjV7Ps38ODCj4r8IKRohpHDlzPP/Dr2U894Q+8l7fe02d2rW3Nv+1qI7M95RfMt/Re1EN6Em7Nv7/49/Pjyg38PP712+eu502/vzt0AWvbRRp51uKHWQgy9zbcggw06+CCElgHYgoDjVXfbeWYh2J9/ru0wRoXU2WYediKMEY6CEaq4IostusicAR+GiF+BGZqI4lodtmaACB/MSCCGJX6g1novGnkkkkkquVmPP15IYm5DcqjjWzyOcUB0s1k4on5lfUjkkmGKOf8mme1ZiaVd4omYn4HGfDklld6JwFSWatIYJGBogVkmn336+SdSPNKZ5n1AQlmWnnDG+QiPQohSZ6FPdmnMFkLsCSimmWpaZqOPEjqgpG1WSuSicPHYhw2Qgsplmzb4cOmmsco6a4Snpvrplmxm6CqppbrFIx8fKILrmjWeFiwbsNK6LLPNLgessMTeeSiyvfoqlwgS2CCGtIZ2iaoByjo7LrnlIsajttxKt6qup4Fr7bXoQmJDt6GeZ8M24aZoLr/9+vuTvPSum6uxZOGrb47XMpqtOR/UMXCxeDbcDsL/Wnxxv+g2/LCWEUM5McIKYyvBECmIAfG0+s0rQsUYu/z/Mq3olnxyxynjtnLIIsssxhgoe4ubDX2wLC7MRRtN5s491/zzX0EPrWicMtMyxiRL2+uAIh/w8XSRR3v9dZJSU201q2JlvXXOCkstBiZktyuGDWa1DDbdda+4dtt2Mu0A3HLD66vUDmASgd5X2wCJ3/vavTjj8QU+eOFlO3B44gnHm21dk2ASua51fGBO5Y2LPjp7gWvOeY2eg861yAuTHN3gkZYtRgqozU067rljFvgtsbNbI+22/10q7xFgIjubS4wRgfCK6/489IUVf/zvtynPfOWt887D4NWXhskWud0ePfnlC7V99wTfBr74wy+6vfHe37AFJiWObz7++SuF/3mW8av/Ff3s576o8S9NmBDD/yIwhiUI0Hn6eyD0tjeLAyZwgQ20HOAK6BkFQoEKNCoHA5Zno/tBsIS4kyAHPUggEIrwgtrT4F1OAYUxBMAEWqECIMbAAHS0iWsm/KHuJNgAGdLQhrXAoQ55OMIBUkmIVdGEQ6BAExto4lCVgwUWs6jFLXKxi178IhjDKMYxkrGMZjwjGtOoxjWysY1ufCMc41hGJ5oAih+Q4geoaEXW6QyGdjKBNQJAhYI17wIxOCQiE6nIRTKykY58JCQjKclJUrKSlrwkJjOpyU1yspOe/CQoKUnHqwBSkITMXh9fVy/JtQ9qrXslLGMpy1nSsoiWtrwlLnOpS9f4EXmn5OMugynMYRKzmMY8JjKTqcxlMrOZznwmNKMpzWlSs5rWvCY2s6nNbXKzm978JjjDKc5xkrOc5jwnOtOpznWys53ufCc84ynPedKznva8Jz7zqc998rOf/vwnQAMq0IEStKAGPShCE6rQhTK0oQ59KEQjKtGJUrSicQkIADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Platelet adherence at a site of vessel wall injury is mediated by von Willebrand factor (vWF) via its interaction with platelet surface receptor glycoprotein (GP) Ib/IX. Platelet aggregation requires fibrinogen (Fgn) bridging that occurs at the GP IIb/IIIa receptor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_27_14783=[""].join("\n");
var outline_f14_27_14783=null;
